Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 1 of 77  
 
FULL PROTOCOL TITL E 
 
B Cell Targeted Treatment I n Myasthenia Gravis:  A Phase II Trial of Rituximab In 
Myasthenia Gravis   
 
 
Protocol Version:  V11.0 
 
 
Protocol Date:  (07/05 /2017) 
 
 
SHORT PROTOCOL TITLE  
 
BeatMG: Rituximab in Myasthenia G ravis  
 
 
 
Protocol Principal Investigator (PPI):  
 
Richard J. Nowak, MD, MS  
Yale University School of Medicine  
 
 
Co-Investigator s (alphabetically) : 
 
Richard J. Barohn, MD  
University of Kansas  Medical Center  
 
Mazen M. Dimachkie, MD  
University of Kansas Medical Center  
 
Jonathan M. Goldstein, MD  
Hospital for Special Surgery/Weill Cornell Medical College  
 
David A. Hafler, MD  
Yale University School of Medicine  
 
Kevin C. O’Connor, PhD  
Yale University School of Medicine  
 
 
 
 
 
 
 
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 2 of 77  
 
 
Supported by:  
The National Institute of Neurological Disorders and Stroke (NINDS)  
 
NeuroNEXT Grant Award: 1U01NS084495-01A1 
Central Coordination Center (CCC): U01NS77179 -01 
Data Coordination Center (DCC): U01NS077352  
 
Study Intervention Provided by:  
 
Genentech/Roche Pharmaceuticals  
 
 
Sponsor of IND/IDE:  
Exempt IND # 116878  
Jonathan M. Goldstein, MD  
 
 
 
The information contained herein is confidential and proprietary in nature, and  will not be 
disclosed to any third party without written approval of authorized designee.  This document may 
be disclosed to the appropriate institutional review boards or to duly authorized representatives 
of the US Food and Drug Administration or a nati onal regulatory authority under the condition that 
they maintain confidentiality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 3 of 77 TABLE OF CONTENTS  
 
OVERVIEW STUDY SCHEMA  ................................ ................................ ................................ . 14 
STUDY OBJECTIVES  ................................ ................................ ................................ .................  15 
1.1 Primary Objectives ................................ ................................ ................................ ........  15 
1.2 Secondary Objectives ................................ ................................ ................................ .... 16 
2 BACKGROUND  ................................ ................................ ................................ ..................  17 
2.1 Rationale  ................................ ................................ ................................ .......................  17 
2.2 Supporting  Data  ................................ ................................ ................................ ............  19 
3 STUDY DESIGN ................................ ................................ ................................ ..................  21 
4 SELECTION AND ENROLLMENT OF SUBJECTS  ................................ .........................  24 
4.1 Inclusion Criteria  ................................ ................................ ................................ ..........  24 
4.2 Exclusion Criteria  ................................ ................................ ................................ .........  25 
4.3 Subject Withdrawal Criteria  ................................ ................................ .........................  26 
4.4 Study Enrollment Procedures  ................................ ................................ .......................  26 
4.4.1  Subject Recruitment and Retention  ................................ ................................ ..........  27 
4.4.2  Screening Logs ................................ ................................ ................................ ..........  27 
4.4.3  Informed Consent ................................ ................................ ................................ ...... 27 
4.4.4  Subject Prednisone Diary  ................................ ................................ ..........................  27 
4.4.5  Randomization/Treatment Assignment  ................................ ................................ .... 28 
5 STUDY INTERVENTIONS/STUDY MEDICATION/STUDY DRUG OR DEVICE  ....... 28 
5.1 Study Medications/Interventions, Administration, and Duration  ................................ . 28 
5.2 Handling of Study Medications/Interventions  ................................ ..............................  29 
5.2.1  Preparation of Rituximab for Administration  ................................ ...........................  30 
5.2.2  Vital Sign Collection and Infusion Monitoring  ................................ ........................  31 
5.2.3  Local Labs Prior to Infusion  ................................ ................................ .....................  31 
5.3 Study Drug Accountability  ................................ ................................ ...........................  31 
5.4 Concomitant Interventions  ................................ ................................ ............................  32 
5.5 Subject compliance  ................................ ................................ ................................ ....... 32 
6 CLINICAL AND LABORATORY EVALUATIONS/STUDY PROCEDURES  ...............  32 
6.1 Schedule of Activities (SOA) – on-intervention period (Screening – Week 52)  .........  33 
6.2 Schedule of Activities (SOA) – optional off -intervention period (Weeks 72 and 96)  . 34 
6.3 Study Staffing  ................................ ................................ ................................ ...............  35 
6.4 Timing of Study Activities ................................ ................................ ............................  35 
6.4.1 Screening Evaluations and Procedures  ................................ ................................ ..... 35 
6.4.2  Baseline Visit Evaluations and Procedures ................................ ...............................  37 
6.4.3  Infusion Visits  ................................ ................................ ................................ ...........  37 
6.4.4  Clinical Study Visits  ................................ ................................ ................................ . 39 
6.4.5  Optional Observational Off -Intervention Follow -up Visits: ................................ ..... 39 
6.4.6  Outcome Evaluations  ................................ ................................ ................................  40 
6.4.7 Laboratory Testing  ................................ ................................ ................................ .... 41 
6.4.8  Prednisone Dose Adjustments  ................................ ................................ ..................  42 
6.4.9  Physical Exam  ................................ ................................ ................................ ...........  45 
6.4.10  Study Medication/Intervention Discontinuation Evaluations/Procedures  ............  45 
6.4.11  Off-Intervention Evaluations  ................................ ................................ ..............  466 
6.4.12  Unscheduled Visits  ................................ ................................ ...............................  47 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 4 of 77 6.4.13  Final On -Study Evaluations  ................................ ................................ ................  477 
6.4.14  Pregnancy  ................................ ................................ ................................ ............  477 
6.5 SPECIAL INSTRUCTIONS AND DEFINITIONS OF EVALUATIONS ..................  48 
6.5.1  Informed Consent ................................ ................................ ................................ ...... 48 
6.5.2  Protocol Violations  ................................ ................................ ................................ . 488 
6.5.3 Documentation of Myasthenia Gravis  ................................ ................................ .... 488 
6.5.4  Medical History  ................................ ................................ ................................ ...... 488 
6.5.5  Treatment History  ................................ ................................ ................................ ..... 49 
6.5.6 Concomitant Medications/Treatments  ................................ ................................ ...... 49 
6.5.7  Immunization during B Cell Depletion ................................ ................................ ..... 49 
6.5.8  Protocol Amendments and Study Termination  ................................ .........................  50 
6.5.9  Clinical Assessments  ................................ ................................ ................................  50 
6.5.10  Laboratory Evaluations  ................................ ................................ .........................  50 
6.5.11  Pharmacokinetic Studies  ................................ ................................ .....................  511 
6.5.12  Subject Adherence Assessments  ................................ ................................ .........  511 
6.5.13  Biomarker/Mechanistic Studies  ................................ ................................ ............  52 
7 MANAGEMENT OF ADVERSE EVENTS  ................................ ................................ ........  52 
8 CRITERIA FOR INTERVENTION DISCONTINUATION  ................................ ...............  53 
9 STATISTICAL CONSIDERATIONS ................................ ................................ ................  533 
9.1 General Design Issues  ................................ ................................ ................................ . 533 
9.2 Outcomes  ................................ ................................ ................................ ......................  55 
9.2.1  Primary Outcome (including definition)  ................................ ................................ ... 55 
9.2.2  Secondary Outcome(s)  ................................ ................................ ..............................  55 
9.2.3 Exploratory Outcomes  ................................ ................................ ............................  555 
9.3 Sample Size and Accrual  ................................ ................................ ............................  566 
9.4 Data Monitoring  ................................ ................................ ................................ ............  57 
9.5 Statistical Analysis Plan  ................................ ................................ ..............................  588 
10 DATA COLLECTION, SITE MONITORING, AND ADVERSE EXPERIENCE 
REPORTING  ................................ ................................ ................................ ..............................  611 
10.1  Data Management  ................................ ................................ ................................ .........  61 
10.1.1  Registration  ................................ ................................ ................................ .........  622 
10.1.2  Data Entry  ................................ ................................ ................................ ...........  622 
10.2  Role of Data Management  ................................ ................................ ..........................  622 
10.3  Quality Assurance  ................................ ................................ ................................ ....... 633 
10.3. 1 Development of Monitoring Plan  ................................ ................................ ....... 633 
10.3.2  Site Monitoring Visits  ................................ ................................ .........................  633 
10.3.3  Laboratory Data Flow  ................................ ................................ .........................  644 
10.4  Adverse Event Reporting  ................................ ................................ ............................  644 
10.4.1  Definitions of Adverse Events, Suspected Adverse Drug Reactions & Serious 
Adverse Events  ................................ ................................ ................................ ...................  666 
10.4.2  Assessment and Recording of Adverse Events  ................................ ...................  688 
11 HUMAN SUBJECTS  ................................ ................................ ................................ .........  711 
11.1  Central Institutional Review Board (CIRB) Review and Informed Consent  .............  711 
11.2 Subject Confidentiality  ................................ ................................ ...............................  711 
11.3  Study Modification/Discontinuation  ................................ ................................ ...........  711 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 5 of 77 12 PUBLICATION OF RESEARCH FINDINGS  ................................ ................................ .... 71 
13 REFERENCES  ................................ ................................ ................................ .....................  73 
SAFETY REPORTING FAX COVER S HEET  ................................ ................................ ...........  77 
GENENTECH SUPPORTED RESEARCH  ................................ ................................ .................  77 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 6 of 77 INVESTIGATOR AGREEMENT  
 
I have read the foregoing protocol  V11.0 07/05 /2017 and agree to conduct the study as described 
herein.  
By signing the protocol, the Investigator agrees to keep all information provided by the 
NeuroNEXT Network in strict confidence and to request the same from his/her staff and the 
Institutional Review Board. Study documents provided by the NeuroNEXT Network  will be stored 
appropriately to ensure their confidentiality. The Investigator should not disclose such information 
to others without authorization, except to the extent necessary to conduct the study.  
 
 
  
 
 
__________________________________  _______________________  
Investigator Signature  Date  
 
__________________________________  
Print Investigator’s Name  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 7 of 77 SIGNATURE PAGE  
Study Number :  
NeuroNEXT  Grant Award : 1U01NS084495-01A1 
Central Coordination Center (CCC): U01NS77179 -01 
Data Coordination Center (DCC): U01NS077352  
 
Principal Investigator Approval:  
 
 Signature:                                                                                   Date:  
 Name:   Richard J. Nowak , MD 
   
 
NeuroNEXT Clinical Coordinating Center Approval:  
 
Signature:                                                                                   Date:  
 Name:  Merit Cudkowicz, MD    
 
NeuroNEXT Data Coordinating Center Approval:  
 
Signature:                                                                                   Date:  
Name:  Christopher Coffey, PhD    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 8 of 77  
LIST OF ACRONYMS, ABBREVIATIONS, AND DEFINITIONS OF TERMS   
Ab   Antibody  
AChR    Acetylcholine Receptor  
AChR+   Acetylcholine Receptor Antibody Positive  
AE   Adverse Event  
AZA   Azathioprine  
CCC    Clinical Coordination Center  
CDE    Common Data Elements  
CFR   Code of Federal Regulations  
CIRB    Central Institutional Review Board  
CMSU  Clinical Materials Services Unit at the University of Rochester Medical 
Center  
CRF   Case report form  
CS   Clinically Significant  
CSS PI   Clinical Study Site PI  
CTCAE   Common Terminology Criteria for Adverse Events  
DCC    Data Coordination Center  
DM   Data Management  
DSMB    Data Safety Monitoring Board  
eCRF    Electronic Case Report Form  
EDC    Electronic data capture  
FDA       Food and Drug Administration  
FVC   Forced Vital Capacity  
GCP    Good Clinical Practice  
HIPAA    Health Insurance Portability and Accountability Act  
ICH   International Conference on Harmonization  
IMM   Independent Medical Monitor  
IVIg   Intraveno us Immunoglobulin  
IST   Investigator Sponsored Trial  
IRB   Institutional Review Board  
MedDRA   Medical Dictionary for Regulatory Activities  
MG   Myasthenia Gravis  
MG-ADL  Myasthenia Gravis Activity of Daily Living  
MGC    Myasthenia Gravis Composite    
MGFA    Myasthenia Gravis Foundation of America  
MG-QOL   Myasthenia Gravis Quality of Life  
MMF    Mycophenolate Mofetil  
MS   Multiple Sclerosis  
MuSK    Muscle Specific Kinase  
MuSK+   Muscle Specific Kinase Antibody Positive  
MTX    Methotrexate  
NCI   National Cance r Institute  
NHL   Non-Hodgkin’s Lymphoma  
NIAID    National Institute of Allergy and Infectious Diseases  
NINDS    National Institute of Neurological Disorders and Stroke  
NSAIDs   Non-steroidal anti -inflammatory drugs  
PIS   Post-intervention Status  
PLEX    Plasma Exchange  
PML   Progressive Multifocal Leukoencephalopathy  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 9 of 77 PPI   Protocol Principal Investigator  
PSC   Protocol Steering Committee  
QMG    Quantitative Myasthenia Gravis  
RA   Rheumatoid Arthritis  
SAE   Serious adverse event  
SLE   Systemic Lupus E rythematosus  
SOA    Schedule of Activities  
URMC    University of Rochester Medical Center  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 10 of 77 SYNOPSIS  
 
Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission with an 
estimated annual incidence of about 1 -2 per 100,000 and prevalence as  high as 20 -50 per 
100,000.1 Treatment consists of symptomatic therapy with acetylcholinesterase inhibitors and 
immunotherapy such as corticosteroids, azathioprine, cyclosporine, plasma exchange (PLEX)  
and intravenous immunoglobulin (IVIg).1-3 Despite current therapies a subset of subject s remain 
medically refractory or have intoler able medication adverse effects.   There is need for another 
agent in the management of MG as there are few effective drugs  for these patients.  Safe, well -
tolerated, efficacious and steroid -sparing therapeutics are needed .   
 
Several recent studies4-6, including two performed by our group 7,8, have demonstrated the 
benefits of B cell depletion rituximab treatment in MG subject s. We completed a small 
retrospective study to e valuate B cell targeted therapy in medically refractory generalized MG 7,8. 
In this analysis we show ed that rituximab led to a sustained clinical improvement in parallel to a 
reduction or discontinuation of other immunotherapies.   
 
We now plan on conducting  a multicenter randomized, double -blind, placebo controlled Phase II  
clinical trial  utilizing a fu tility design . The study would include acetylcholine receptor ( AChR ) 
antibody positive generalized MG subject s. This study also presents a unique opportunity to study 
both drug and disease mechanisms because unlike many other autoimmune diseases in which 
rituximab has been used, MG affords the investigation of antigen -specific components that 
participate in the immunopathology of the disease , namely  autoantibodies, autoantibody -
producing B cells , and antigen -specific T cells. This work will further our und erstanding of MG 
immunopathology and it represents the first step toward gaining a more complete understanding 
of the immune mechanisms underlying treatment of MG with rituximab leading to new ways to 
treat the disease.  
 
The specific aim of this study is t o determine whether rituximab is a safe and effective treatment 
for subjects with MG.  Although not part of the current protocol, we believe that adding 
exploratory mechanistic studies to the protocol would be important in order to identify 
biomarkers that  can potentially be used in future MG clinical trials as well as exploring whether 
B cell therapy is effective in MG.   With this in mind, the investigators have received funding in 
full support of an  exploratory mechanistic study with extended follow -up through the National 
Institute of Allergy and Infectious Diseases (NIAID). In addition, NINDS has awarded funding in 
support of the extended clinical follow -up visits.  
 
Study Title  
 
Full Title: B Cell Targeted Tr eatment in Myasthenia Gravis: A Phase II Trial of Rituximab In 
Myasthenia Gravis   
 
Short  Title: BeatMG:  Rituximab in Myasthenia Gravis  
 
Objectives   
 
The specific primary objective  of this study is to determine whether rituximab is a safe and 
beneficial therapeutic for MG that warrants further study in a phase III efficacy trial.  The primary 
clinical endpoint will be the steroid sparing effect of rituximab . Our retrospective study s howed 
that rituximab treatment had a measurable and significant effect on conventional 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 11 of 77 immunosuppression, specifically demonstrating an unmistakable prednisone dose reduction7.  
Importantly, steroid -reduction was recently demonstrated to be a practical outcome measure in a 
MG trial by an independent group9. Also in 2012, the Task Force on MG Study Design of the 
Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America (MGFA) 
recommended steroid -sparing effect as a clinical outcome measure10. Our first primary outco me 
measure is the percent of subjects  achieving ≥ 75% mean daily prednisone dose reduction in the 
4 weeks prior to week 52 and with clinical improvement or no worsening of symptoms .  Our 
second primary outcome is s afety and will be assessed by examining th e frequency of study -
related adverse experiences between the treatment and placebo  groups . 
 
Design and Outcomes  
 
We plan a multicenter randomized, double -blind, placebo controlled Phase II clinical trial 
evaluating the safety and steroid -sparing effect of rituximab in MG. The study w ill include  50 
AChR antibody positive generalized MG subject s.  We plan to  enroll 25 subjects in a treatment 
group and 25 subjects in a  control placebo group.  
 
Primary Outcomes:  
1. Steroid Sparing Effect:   Percent of subjects tha t achieve a ≥ 75% reduction in mean daily 
prednisone dose in the 4 weeks prior to week 52 and with clinical improvement or no 
significant worsening of symptoms ( ≤ 2 point increase  in MG composite score ) as 
compared to the 4 -week period prior to randomizati on and initiation of treatment.  
2. Safety  
 
Secondary Outcomes:  
1. Evaluate whether there is a trend toward clinical benefit as measured by MG -specific clinical 
outcome scales used as endpoints in prior clinical trials.  We will determine if rituximab can 
signif icantly improve the scores  of the following MG -specific clinical outcome measures:   
a.   Myasthenia Gravis Composite (MGC) score  
b. Quantitative Myasthenia Gravis (QMG) score  
 
Interventions and Duration  
 
Intervention (rituximab): The t reatment group will receive a total of two cycles of rituximab 
separated by 6 months. Each cycle is defined as one infusion  (375mg/m2 IV) per week for four 
consecutive weeks. As such, cycle 1 will be administered weeks 0-3 and cycle 2 will be given 
weeks 24 -27. The placebo gr oup will receive a vehicle control infusion.   A predetermined steroid 
taper schedule for both treatment (rituximab) and placebo groups will be utilized. In each subject, 
the prednisone dose will be gradually reduced based on the steroid taper schedule begi nning at 
week 8. The dose will only be reduced after confirming clinical improvement or stable symptoms 
based on the MGC score (≤ 2 point increase ). 
 
Duration: We set a study period of 52 weeks based on the delayed benefits observed following 
rituximab treatment and in the setting of utilizing a two -cycle protocol. The extended time points 
are needed as normalization of B cell counts typically takes 12+ months fo llowing B cell depletion 
treatment.  In order to assess safety in the B cell recovery period  as well as assess the long -term 
durability of response , there are two additional optional observational off study -intervention  time 
points (weeks 72 and 96). The subject s will be treated per medical standard of care during this 
period.    
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 12 of 77  
Evaluations: Subject s will have clinical evaluations at baseline and then every 4 weeks thereafter 
(week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52) .  Clinical evaluations w ill be completed by a 
blinded evaluator . The dose of prednisone will be recorded by each subject  daily and collected at 
each scheduled assessment . Post -intervention status (PIS) will be assessed by measuring MGFA 
class, MGC, QMG, MG -ADL and MG -QOL scores. Adverse effects will be monitored to assess 
safety and tolerability in this subject  population per the NINDS Guidelines for Data and Safety 
Monitoring in Clinical Trials . A limited  clinical assessment per standard of care will be completed 
during the optio nal off study -intervention  follow -up period at weeks 72 and 96.   
 
Blinding  
This is a double -blind clinical trial.  All study subjects and Clinical Study Staff will be blinded to 
treatment assignment.   The Clinical Study Site Investigator is responsible reviewing all adverse 
events and adjusting subjects’ prednisone dose based on the Myasthen ia Gravis Composite 
(MGC) score  without  knowing whether a subject has received drug or placebo.   The clinical 
evaluators who determine the secondary outcome m easures, Myasthenia  Gravis Composite 
(MGC) and Quantitative Myasthe nia Gravis (QMG) , are bl inded to treatment assignment and 
clinical adverse event information.  Site Pharmacists will be the only staff who have access to 
treatment information.    
 
Sample Size and Population  
 
Sample Size: 50  
 
Population: Generalized AChR Antibody Positive (AChR+) Myasthenia Gravis  
 
Randomization will be performed through an interactive website, and will be stratified based on 
the steroid dose at baseline: moderate dose pred nisone (15 -35 mg/day) and high dose 
prednisone (>35 mg/day) as well as their treatment at baseline, prednisone only versus 
prednisone plus another immunosuppressive therapy (IST ). Subjects will be assigned a study ID 
at the time of enrollment.  The study I D includes the identification of the center and a unique 
subject ID.  The DCC will generate a randomization table for each of the strata using a permuted 
block design with random block sizes.  
 
Inclusion Criteria:  
 
1. Subject s 21 to 90 years old  
2. Subjects must have generalized MG, defined as MGFA clinical classification grades 
2 (mild), 3 (moderate), or 4 (severe, but not intubated) at the time of 
screening /randomization . 
3. Elevated AChR antibody titer  
4. Subject’s signs and symptoms should not be better explained b y another disease 
process.  
5. Subjects must be on a stable standard immunosuppressive regimen:  
a. Prednisone only:  Prednisone dose must be at least 15mg/day (or the equivalent 
on alternate days), and the dose of prednisone must have been stable for at least 
4 weeks (28 days) prior to the baseline visit.  
b. Prednisone plus another immunosuppressive therapy (IST).  Immunosu ppressive 
therapies other than prednisone, specifically  azathioprine, mycophenolate 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 13 of 77 mofetil, cyclosporine, tacrolimus or methotrexate, are permitted, but the dose 
must have been stable for at least 6 months prior to the baseline visit.   
(Note: The predniso ne dose must be stable as defined in the prednisone only 
group. The IST dose must remain stable throughout the course of the stud y). 
6. Subject s must be willing to complete the study and return for follow -up visits.  
7. No history of thymoma, tumor, infection, or interstitial lung disease on chest CT, MRI, 
or chest x -ray. Note: Chest x -ray will be completed at screening to look of interstitial 
lung disease.  A chest CT or MRI to evaluate for thymoma must be completed as 
part of prescreening.  
8. Able and willing to give written informed consent and comply with the requirements 
of the study protocol . 
9. Subject s must be able to give written informed consent before participating in this 
study. A copy of the signed consent must be kept in the subject ’s medical record.  
10. Men and women of reproductive potential must agree to use an acceptable method 
of birth control during treatment and for twelve months (1 year) after completion of 
treatment . 
 
Exclusion Criteria:  
 
1. A history of chronic degenerative, psychiatric, or neurologic disorder other than MG 
that can produce weakness or fatigue.  
2. Other major chronic or debilitating illnesses within six months prior to study entry.  
3. Female subject s who are premenopausal and are:  
(a) pregnant on the basis of a serum pregnancy test,  
(b) breast -feeding, or  
(c) not using an effective method of double barrier (1 hormonal plus 1 barrier method 
or 2 simultaneous barrier methods)  or birth control (birth control pills, male condom, 
female condom, intrauteri ne device, Norplant, tubal ligation, or other sterilization 
procedures).  
4. Altered levels of consciousness, dementia, or abnormal mental status.  
5. Thymectomy in the previous six months.  
6. Subject s who have been medicated with immunosuppressive drugs not listed i n 
inclusion #5 within the last 8 weeks (56 days)  prior to the baseline visit  
7. Subjects who have been medicated with an immunosuppressive agent such as 
azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus or methotrexate , that 
is withdrawn within 8 weeks (56 days) of the Baseline Visit.  
8. Subjects who have received  IVIg or PLEX treatment  within the last  4 weeks (28 
days)  prior to the baseline visit .   
9. Unstable dose or a stable dose of > 480 mg/day  of pyridostigmine in 2 weeks prior to 
screening visit . 
10. Daily use of non -steroidal anti -inflammatory drugs (NSAIDs).  
11. History of renal or hepatic insufficiency or elevated liver enzymes  (AST or ALT >2.5 x 
Upper Limit of Normal) . 
12. History of bone marrow hypoplasia, leucopenia, throm bocytopenia, significant 
anemia, clinical or laboratory evidence of immunodeficiency syndromes , that are not 
transient events or side effects related to a clinical procedure (i.e. plasmapheresis) 
and within one year of screening.  
13. Forced Vital Capacity (FVC ) <50% of percent predicted.  
14. ANC < 1.5 x 103 cells/microliter  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 14 of 77 15. Hemoglobin:  < 8.0 gm/dL   
16. Platelets:  < 100,000/mm  
17. Positive Hepatitis B or C serology (Hep B surface antigen and Hep C antibody)  
18. History of positive HIV (HIV conducted during screening if applicable)  
19. Treatment with any investigational agent within 4 weeks of screening or 5 half -lives 
of the investigational drug (whichever is longer)  
20. Receipt of a live vaccine within 4 weeks prior to randomization  
21. Previous t reatment with rituximab (MabThera ® / Rituxan ®) 
22. Previous treatment with natalizumab (Tysabri ®) 
23. History of severe allergic or anaphylactic reactions to humanized or murine 
monoclonal antibodies  
24. History of recurrent significant infection or history of recurrent bacterial infections  
25. Known activ e bacterial, viral fungal mycobacterial, or other infection (including 
tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail 
beds) or any major episode of infection requiring hospit alization or treatment with IV  
antibiotic s within 4 weeks of screening or oral antibiotics within 2 weeks prior to 
screening  
26. Unstable steroid dose in the past 4 weeks  (28 days)  
27. Lack of peripheral venous access  
28. History of drug, alcohol, or chemical abuse within 6 months prior to screening  
29. Concomit ant malignancies or previous malignancies, with the exception of 
adequately treated basal or squamous cell carcinoma of the skin or  carcinoma in situ 
of the cervix  or prostate . 
30. History of psychiatric disorder that would interfere with normal participation in this 
protocol  
31. Significant cardiac or pulmonary disease (including obstructive pulmonary disease)  
32. Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding giving reasonable suspicion of a disease or conditio n that 
contraindicates the use of an investigational drug or that may affect the interpretation 
of the results or render the subject  at high risk from treatment complications . 
33. Subjects that do not record daily prednisone doses for at least 28 days before t he 
Baseline visit, or subjects whose prednisone dose varies by ≥6mg/day on average.  
34. Prednisone dose of more than  100 mg/day  (or 200 mg over a  two d ay period ). 
 
OVERVIEW STUDY SCHEMA  
 
A randomized, double -blind, placebo controlled clinical trial schematic is shown  below . A total of 
50 AChR+ MG subjects will be enrolled (25 in a treatment arm and 25 in a placebo arm). The 
subjects will be evaluated every 4 weeks for 52 weeks after initial treatment  along with two 
additional optional observational off study -intervention  time points at weeks 72 and 96.  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 15 of 77  
 
STUDY OBJECTIVES  
1.1 Primary Objectives  
 
Several recent studies 4-6, including two performed by our group 7,8, have demonstrated the 
benefits of B cell depletion rituximab treatment in MG subject s. We completed a small 
retrospective study to e valuate B cell targeted therapy in medically refractory generalized MG 7,8. 
In this analysis we show ed that rituximab led to a sustained clinical improvement in parallel to a 
reduction or discontinuation of corticosteroid therapy and plasma exchange treatments. We 
observed a prednisone dose reduction by a mean of 65%, 86% and 94% after one, two and three  
cycles of rituximab, respectively (Figure 1 ). 
 
The specific primary aim  of this study is to determine whether rituximab is a safe and beneficial 
therapeutic for MG that warrants further study in a phase III efficacy trial.  The primary clinical 
endpoint will be the steroid sparing effect of rituximab  (mean daily prednisone dos e in the last 4 
weeks of the study). Our retrospective 
study showed that rituximab treatment 
had a measurable and significant effect 
on conventional immunosuppression, 
specifically demonstrating an 
unmistakable prednisone dose 
reduction . Importantly, steroid -reduction 
was recently demonstrated to be a 
practical outcome measure in a MG trial 
by an independent group 9. Also in 2012, 
the Task Force on MG Study Design of 
the Medical Scientific Advisory Board of 
the Myasthenia Gravis Foundation of 
America (MGFA) recommended 
steroid -sparing effect as a clinica l 
outcome measure 10.  
 
Primary Outcome 1.  Our first primary outcome measure i s the percent  of subjects that achieve a 
≥ 75% reduction in mean daily prednisone dose in the 4 weeks prior to week 52 and with clinical 
improvement or no significant worsening of symptoms (≤ 2 point increase  in MG Composite score ) 
 
 
Figure 1. Effect of rituximab on conventional 
immunosuppression.  Prednisone dose reduction following 
treatment with cycles 1 through 3 of rituximab. The mean dose 
reduction of the MG subject cohort (n=14)  following each cycle 
of treatment was calculated as reduction of baseline dose given 
prior to treatment  

Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 16 of 77 as compared to the 4 week period prior  to randomization and initiation of treatment.  Statistical 
considerations, including futility design , will be further discussed in section 9.  
 
Primary Outcome 2.   Our second primary outcome is s afety and will be assessed by examining 
the frequency of study -related adverse experiences in the two groups  (treatment vs. placebo) .   
 
1.2 Secondary Objectives  
 
The main secondary objective is to evaluate whether there is a trend toward clinical benefit as 
measured by MG -specific clinical outcome scales.  If successful , measures studied would lay the 
groundwork toward optimizing the design of a subsequent phase III efficacy trial of rituximab in 
MG.   
 
Secondary Outcomes.   Our secondary outcomes will focus on whether there is a trend toward 
clinical benefit as measured by MG -specific clinical outcome scales used as endpoints in prior 
clinical trials.  We will determine if rituximab can significantly improve the scores of t he following 
MG-specific clinical outcome measures:  (1) Myasthenia Gravis Composite score (MGC).   (2) 
Quantitative Myasthenia Gravis  score  (QMG) .10 11-13 These studied measures would lay the 
groundwork toward optimizing the design of a subsequent phase III efficacy trial of rituximab in 
MG.   
 
Additional explorat ory clinical outcomes  will be investigated to monitor effectiveness as well as 
evaluate other endpoints that would be useful in optimizing future MG trial designs as well as a 
Phase III rituximab trial.   
 
Clinical Exploratory Outcomes.  
We will determine if rituximab can significantly improve the scores of the following outcome 
measures: (1) MG -Activities of Daily Living (MG -ADL) .14 (2) MG -Quality of Life (MG -QOL).15  
 
Other previously used me asures of steroid -sparing effect will be assessed: (1) Mean daily 
prednisone dose at each scheduled assessment (every 4 weeks). (2) A delayed start of the area 
under the dose -time curve (AUDTC), starting at week 8. (3) Percentage of subject s achieving a ≥ 
50% mean daily prednisone dose reduction with main tenance of minimal or no symptom s in 4 
weeks prior to week 52.  (4) Body Mass Index (Screening Visit and weeks 24 and 52).  (5) HbA1C  
(Screening Visit and week 52).  
 
MG flare rate (failure of therapy) will b e assessed by: (1) Number of rescue treatments (PLEX or 
IVIg) . (2) Number of times prednisone dose needed to be increased. (3) Frequency of a ≥ 3 -point 
increase in the MGC score.  
 
Additionally, there will be two  optional  observational off study -intervention time points (weeks 72 
and 96) The primary focus will be to assess B cell recovery/repopulation as a safety measure.  
Specifically, we will examine: (1) Percentage of subjects achieving normal B cell counts at week 
72 and 96.  (2) Percentage of  achieving baseline B cell counts at week 72 and 96. (3) Percent B 
cell recovery to normal or baseline levels.  In addition, the long -term durability of response will 
also be assessed.  Specifically, we will examine : (1) P ercentage of subject s achieving a sustained 
≥ 75% mean daily prednisone dose reduction . (2) Percentage of subject s achieving a ≥ 50% mean 
daily prednisone dose reduction . (3) Prednisone AUDTC (if applicable). (4) Clinical status as 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 17 of 77 measured by MGFA Class, MGC, MG -QOL and MG -ADL scores. (5)  Number of rescue 
treatments (PLEX or IVIg) . 
 
Biomarker/Mechanistic Exploratory Outcomes . 
The biomarker or mechanistic studies are focused on identifying how treatment modifies the 
immunopathology of MG. We will study changes in the antigen specific  components of the MG 
immune system. We have developed/adapted immunoassays so that we can examine 
autoantibodies, B cells and T cells. The principal mechanistic outcome  will be the decrease in titer 
of circulating AChR autoantibodies within an individual.  Other e xploratory mechanism -based 
outcomes  include determining how rituximab modifies antigen -specific B cell frequency, the B cell 
repertoire, B cell activating factor (BAFF) levels and whether rituximab modifies antigen -specific 
T cell frequency and phe notype. Measurements will be performed prior to and during B cell 
depletion and through repopulation of the B cell compartment, which will be of particular interest 
in terms of assessing the durability of the treatment.   Blood will be collected for mechani stic 
studies at the Baseline Visit,  and at w eeks 24, 52, 72 and 96 . 
 
2 BACKGROUND  
2.1 Rationale  
 
Overview . Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission 
with an estimated annual incidence of about 1 -2 per 100,000 and prevalence as high as 20 -50 
per 100,000.1, 16  Treatment consists of symptomatic therapy with acetylcholinesterase inhibitors 
and immunotherapy such as corticosteroids, azathioprine, cyclosporine, pl asma  exchange 
(PLEX)  and intravenous immunoglobulin (IVIg).1-3 Despite current therapies a subset of subjec ts 
remain medically refractory or have intolerable medication adverse effects.  
 
Project Rationale . Autoreactive B cells play an important role in the immunopathogenesis of MG 
and as such would seem to be appropriate for targeted drug therapy investigation.17 Recent 
examples from other autoimmune disorders such as rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE) and multiple sclerosis (MS), which also frequently have poor response to 
current conventional therapy and frequent relapses or ref ractory disease, have suggested benefit 
with B cell directed therapies.18-21 B cell depletion may therefore be a beneficial therapeutic goal 
in certain autoimmune diseases base d on this experience22 and may potentially tra nslate into a 
new treatment strategy for MG, particularly in those subject s who have failed and are resistant to 
other medical therapies.     
 
Rituximab is the only B cell directed biologic approved for use clinically.  It is a chimeric 
monoclonal antibody  that targets the CD20 antigen found on B lymphocytes and modulates B cell 
activation.  CD20 is a 33 -kDa protein expressed by all mature B cells, but not on pre -B or 
differentiated plasma cells.  Rituximab has been used as part of the standard therapy for non-
Hodgkin’s lymphoma (NHL) as well as a number of autoimmune diseases.18,23,24 , Interest in its 
use for MG began after Gajra and coworkers reported a subject  with both lymphoma and MG who 
responded favorably to rituximab.25 Since that time several groups, including our own, have 
observed the benefits of rituximab in autoimmune MG subject s.4-8,26-33 It is, however, unclear what 
changes in the cellular and molecular immune system are associated with the clinica l 
improvement.  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 18 of 77 The observed positive effect of rituximab in subject s with MG, based largely on anecdotal reports, 
is promising and suggests that further investigation of this agent in MG is warranted (refer to 
Table 1 ).34 The ration ale for the current proposal is to follow our pilot retrospective study with a 
prospective study to more carefully assess the safety, tolerability and identify biomarkers in this 
subject  population  as well as determine whether it is beneficial therapeutic,  employing  a futility 
trial design, that warrants further study in a phase 3 efficacy trial .7,8,35  In addition, we will  initiate 
an examination of the changes in the cellular immune system that are associated with the clinical 
improvement to further define the immune mechanisms associated with treatment by measuring 
immune components, which participate in the pathology of MG, prior to and after immunotherapy.  
This work is significant because it addresses an important and intractable immune -mediated 
problem involving the neuromuscular junction as well as helps further our understanding of the 
immunopathology of MG.   It also represents,  for the first time in MG, the application of targeted 
therapy.  The study of immunologic biomarkers will help elucidate potentially important differences 
in subject s that are responders and non -responders to B cell directed therapy.   This may give 
insigh t into further development of individual subject  tailored therapies in the future.    
 
Table 1:  Key Reports of Rituximab in Myasthenia Gravis  (adapted from Ibrahim et al.)34 
 
Study  Year Subject 
number  Controll
ed Grade of 
Evidenc
e Dose of rituximab  Outcomes  
Illa et al  
 2008  6 No D 375 mg/m2 every 
week for four 
consecutive weeks   Improvement of clinical and 
laboratory parameters, 
especially in the 3 MuSK+ 
cases  
Lindberg et 
al 2010  5 No D 375 mg/m2 every 
week for four 
consecutive weeks, 
retreatment with 
1000 mg  weekly x2  Slow but remarkable 
reduction in MG symptoms.  
Maddison et 
al 2010  12 No C 375 mg/m2 every 
week for four 
consecutive weeks  8 improved,4 subject did not 
have significant benefit  
Tandan et al  
Stieglbauer 
et al 
Lebrun et al  
 
 
Nelson et al  
 2010  
2009  
 
2009  
 
 
2009  10 
3 
 
6 
 
 
3 No 
No 
 
No 
 
 
No 
 C 
D 
 
D 
 
 
D Ongoing pilot study  
Guided by the total 
count of peripheral B 
lymphocytes  
375 mg/m2 every 
week for four weeks 
then 2 -monthly dose 
of 375  mg/m2 
375 mg/m2 every 
week for four 
consecutive weeks, 
one subject received 
only one dose  Ongoing pilot study  
Improved  
 
3 MuSK+, 1 AChR+ and 2 
double seronegative 
improved  
 
3 MG cases with thymoma 
responded with stabilization 
and reductions in 
immunosuppressive 
medications  
Kundi et al   2010  3 No D 1 gram (750mg/m2) 
repeated twice  1 MuSK+, 1 AchR+ and 1 
double seronegative 
improved  
Nowak et al  2011  14 No  C 375 mg/m2 every 
week for four, 
repeated every 6 mo  6 AChR+ and 8 MuSK+ 
subjects showed clinical 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 19 of 77 Study  Year Subject 
number  Controll
ed Grade of 
Evidenc
e Dose of rituximab  Outcomes  
improvement and significant 
steroid dose reduction  
 
Blum et al  2011  14 No C 1 gram in 2 divided 
doses  11 subjects clinically 
improved and 12 were able 
to reduce other 
immunotherapies  
 
Diaz-Manera 
et al 2012  17 No C 375 mg/m2 every 
week for 4 weeks, 
then monthly x 2 
months  6/6 MuSK+ subjects 
achieved remission or 
minimal manifestation 
status; 10/11 AChR+ 
subjects improved with 6/10 
subjects needing reinfusion 
6-34 mo after 1st dose.  
 
 
There is a paucity of proven steroid -sparing agents in the management of MG.  The most 
convincing steroid -sparing agent is azathioprine ( AZA) with some recent evidence supporting 
methotrexate ( MTX ).36,37 The current mycophenolate mofetil ( MMF ) and tacrolimus data are not 
very strong  but are suggestive of some benefit.9,38  There is need for another agent in the 
management of MG as there are few effective drugs, as well as a subset of subject s that are 
medically refractory or drug -resistant to standard therapies. Safe, wel l-tolerated, efficacious and 
steroid -sparing therapeutics are needed .   
Protocol Rationale . A standard protocol for rituximab infusion in MG has not been established.  
Therefore, the non-Hodgkin’s Lymphoma (NHL) treatment protocol was adopted which consist s 
of weekly infusions at 375 mg/m2.   One cycle is defined as 1 infusion per week for 4 consecutive 
weeks.   The i nterval between cycles is 6 months.  We have based our decision to use a two -
cycle regimen, instead of a single cycle approach, on the following evidence. A recently published 
European series evaluating the long -term effects of rituximab following one cycle did show clinical 
improvement 4. While clinical improvement was achieved, an immunotherapy -free remission state 
was not . Fifteen of 17 subject s continued to remain on prednisone and/or additional 
immunotherapy. Six out 10 AChR+ subject s in this study needed to be retreated to maintain initial 
clinical benefits. We believe that an additional treatment cycle may be indicated  to achieve a 
durable response in parallel to successful withdrawal/reduction of steroids and/or other chronic 
immunotherapy. Retrospective analysis of twenty MG subject s followed in our neuromuscular 
clinic has shown that only 5 of 20 subject s were immuno therapy -free after completing one cycle 
as compared to 12 of 20 following two cycles. Mean steroid dose was reduced by 65% and 86% 
following one and two cycles, respectively. This suggests that a two -cycle protocol may be more 
clinically advantageous  in MG  and serves as the basis for our approach.   Retrospective analysis 
of our data with the DCC also revealed that 82% of subjects  who received rituximab achieved at 
least a 75% reduction in their prednisone dose at 52 weeks (95% CI: 48% -98%).   This statistica l 
analysis is the basis for our primary endpoint.  
2.2 Supporting Data  
 
The first reports on the use of rituximab in MG were in subject s treated for lymphoma.25,39 In three 
of these subject s, rituximab was administered at 375 mg/m2 weekly for four weeks, a nd in one, the 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 20 of 77 dose was 260 mg/m2 weekly for four weeks. Clinical symptoms of MG such as diplopia and muscle 
fatigability as well as pulmonary function tests showed improvement with a decrease in the serum 
AChR antibody levels.  
 
This was followed by the pu blication of several small and one large uncontrolled case series. In 
2008, Illa and co -workers reported treating six severe refractory MG subject s (three AChR+ and 
three MuSK+  (Muscle Specific Kinase Antibody Pos itive)) with rituximab at 375 mg/m2 weekly for 
four weeks.5 All six cases (five MGFA Grade IVb and one Grade V) dramatically improved clinically.  
There was a decline in serum antibody titers in both AChR+ and MuSK+ groups.  There appeared 
to be a more sustained clinical improvement in the MuSK+ group.   No severe adverse events were 
reported.  
 
Investigators in the United Kingdom reported data obtained from a nationwide survey of physicians 
treating MG.27 They identified ten subject s diagnosed with generalized MG (seven AChR+ and 
three MuSK+) and two with Lambert -Eaton myasthenic syndrome. Rituximab was administered in 
standard doses in eight cases, whereas the rest received one or two infusions at 375 mg/m2. Over 
the 4 to 48 month follow -up period, three of seven AChR+ MG cases improved on their MGFA 
post-interventio n status, whereas all MuSK+ cases improved. Both Lambert -Eaton myasthenic 
syndrome cases improved but did not achieve remission. Four subject s did not have significant 
benefit from rituximab, three of which received fewer than four infusions.  
 
There are ot her small case series that have suggested similar efficacy of rituximab in generalized 
MG.8,29,30 Lebrun and coworkers evaluated  six bedridden MG cases; one was AChR+, three had 
MuSK+, and two were double -seronegative cases.6 Rituximab was administered at 375 mg/m2 on 
Days 1, 8, 15, and 21 during the first month and then one dose every 2 months. All subject s 
responded very well to rituximab with significant clinical improvement  allowing for the tapering of 
prednisone and pyridostigmine bromide.  
 
Our group has recently completed a retrospective study of fourteen subject s to evaluate B cell 
targeted therapy in medically refractory generalized MG, including both MuSK+ and AChR + 
antibody subject s.7 Rituximab was given at a standard dose of 375 mg/m2 weekly.  Each cycle 
was defined as one infusion per week for four consecutive weeks. Interval between cycles was 
set at 6 months.  In this analysis, we showed that rituximab led to a sustained clinical improvement 
in parallel to a reduction or discontinuation of corticosteroid  therapy and plasma exchange 
treatments. We observed a prednisone dose reduction by a mean of 85.7% and 93.8% after two 
and three cycles of rituximab, respectively.  AChR antibody titers significantly decreased by a 
mean of 52.1% after the second cycle (p = 0.005).  
 
A group in Europe recently published a report describing seventeen drug -resistant MG subject s 
treated with rituximab (six MuSK+ and eleven AChR+).4 After a mean post -treatment period of 31 
months, ten of the AChR+ subject s improved but six of them needed reinfusions. In contrast, all 
MuSK+ subject s achieved a remission or min imal manifestations status and no need for 
reinfusions. Consequently, in the MuSK+ group, prednisone doses were reduced (average dose 
before rituximab: 49 mg/day; at last visit: 6.5 mg/day) and other immunotherapies could be 
withdrawn. Clinical improvement  was associated with a significant decrease in the antibody titers 
only in the MuSK+ subject s (mean reduction of 86.7%, p = 0.002). MuSK antibody levels were 
either negative or decreased at the last follow -up period. They concluded that rituximab has long -
lasting benefits in MuSK+ subject s and recommend rituximab as an early therapeutic option in 
this group of subject s with MG if they do not respond to steroids. AChR+ subject s also responded 
to treatment but required repeat treatment.     
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 21 of 77 To date, approxima tely seventy -five cases of MG treated with rituximab have been reported.  The 
majority of subject s were observed to benefit from treatment.  In the absence of a controlled, 
prospective clinical trial and reporter bias for positive studies, it is difficult to firmly conclude that 
rituximab is an efficacious therapeutic in MG.  The evidence thus far warrants further investigation.   
 
The safety of ritux imab therapy is an important concern. The most common side effect reported 
is an infusion reaction consisting mainly of fever, rigors, nausea and hypotension.  Progressive 
multifocal leukoencephalopathy (PML) is the most significant complication, however, the relative 
risk is thought to be low per a recent review40. Per this review, there have been a total of 57 PML 
cases following rituximab therapy in HIV -negative patients from 1997 to 2008.  These numbers 
are based on cases reported to the Food and Drug Administration (FDA) as well as reported in 
the medical li terature. Fifty -two of the cases were patients with B -cell lymphoproliferative 
disorders and the remaining 5 cases were patients with an autoimmune disorder (i.e., SLE, 
rheumatoid arthritis, autoimmune pancytopenia).  There have been no cases of PML report ed in 
MG subject s treated with rituximab.  We plan to minimize concomitant immunosuppressive 
therapies in our subject s and plan to enroll subjects who are either only on prednisone or on 
prednisone plus only one other IST.  Please refer to eligibility crit eria for specific details.  These 
regimens represent real world scenarios and are also consistent with the types of patients 
included in our pilot study7.  We recommend this type of approach prior to initiating rituximab as 
combination treatments could pos e a higher PML risk.   
 
Please refer to the study drug package insert for additional details.   
3 STUDY DESIGN  
 
Clinical Trial Design.  We propose a 
multicenter randomized, double -blind, 
placebo controlled clinical trial 
evaluating the safety and steroid -
sparing effect of rituximab in MG. The 
study would enroll  AChR  antibody 
positive generalized MG subject s 
(Figure 2). Based on sample size 
calculations we propose a study of 50 
total subject s. We expect to enroll 25 
AChR+ subjects in a treatment group 
along with 25 subjects in a control 
placebo group.  
 
Subject s. Subjects who are on 
standard of care treatment regimens 
for MG may enroll.  Each previously 
diagnosed generalized MG subject  at 
time of enrollment will be expected to be on a stable fixed dose of prednisone (minimum dose of 
15 mg/day) for at least 4 weeks (28 days) with stable symptoms. Prednisone dose variation would 
be limited to less than 6 mg/day on average in the 4 weeks (28 days) prior to the start of the study  
or randomization . There will be two groups of standard of care treatment regimens and are d efined 
as: 
• Prednisone only.   
 
Figure 2. Schematic diagram outlining trial design.  A 
randomized, double -blind, placebo controlled clinical trial is shown. 
A total of 50 AChR + subject s would be enrolled (25 in a treatment 
arm and 25 in a placebo arm). The subjects will be evaluated every 
4 weeks for 52 weeks after initial treatment.  There are two 
additional  optional time points at weeks 72 and 96 in order to follow 
B cell rec overy and long -term durability of response.  
 

Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 22 of 77 • Prednisone plus another IST.   The prednisone dose must be as defined above and the 
subject must be on a stable dose for at least 6 months prior to baseline on one of the 
following IST:  azathioprine, mycophenolate mofetile, cycl osporine, tacrolimus or 
methotrexate.  
 
Study Duration.  We set a study period of 52 weeks based on the delayed benefits observed 
following rituximab treatment and in the setting of  utilizing a two -cycle protocol.  
 
In order to assess the long -term durabilit y of response, there are two additional optional 
observational off study -intervention  time points (weeks 72 and 96). The subject s will be treated 
per medical standard of care during this period.   The extended time points are also needed as 
normalization of B cell counts typically takes 12+ months following B cell depletion treatment.  
 
Randomization.   Randomization will be performed through an interactive website, and will be 
stratified based on t he steroid dose at baseline: moderate dose prednisone (15 -35 mg/day) and 
high dose prednisone (>35 mg/day)  as well as standard of care treatment regimen at the baseline 
visit (prednisone only vs. prednisone plus another IST) . Subjects will be assigned a st udy ID at 
the time of enrollment.  The study ID includes the identification of the center and a unique subject 
ID.  The DCC will generate a randomization table for each of the strata using a permuted block 
design with random block sizes.  
 
Blinding .  This is a double -blind clinical trial.  All study subjects and Clinical Study Staff will be 
blinded to treatment assignment.  The Clinical Study Site Investigator is responsible reviewing all 
adverse events and adjusting subjects’ prednisone dose based on the Myasthen ia Gravis 
Composite (MGC) score  without  knowing whether a subject has received drug or placebo.   The 
clinical evaluators who determine the secondary outcome measures, Myasthenia  Gravis 
Composite (MGC) and Quantitative Myasthenia Gravis (QMG) , are bl inded to treatment 
assignment and clinical adverse event information.  Site Pharmacists will be the only staff who 
have access to treatment information.    
 
Rituximab . Treatment group will receive a total of two cycles of rituximab ( 375mg/m2) separated 
by 6 months. Each cycle is defined as one infusion per week for four consecutive weeks. As such, 
cycle 1 will be administered weeks 0-3 and cycle 2 will be given weeks 24 -27. The placebo group 
will receive an infusion that contains only the veh icle components of the rituximab solution.    
 
Prednisone.  A predetermined steroid taper schedule for both treatment (rituximab) and placebo 
groups will be utilized. In each subject, the prednisone dose will be gradually reduced based on 
the steroid taper s chedule beginning at week 8. The dose will only be reduced after confirming 
clinical improvement or stable symptoms based on the MGC score (≤ 2 point increase)  as 
compared to the Baseline Visit or prior study visit MGC score . If the MGC score change is ≥ 3  
points , the prednisone dose would be increased until symptoms resolved or at least stabilized to 
baseline status (baseline  visit MGC score). After symptom stabilization, prednisone taper can 
again be resumed at next scheduled assessment. Subject s would co ntinue in the study even if 
they could not taper off higher doses of steroids (40 -60 mg/day) as long as their symptoms were 
controlled on that dose as this would be considered standard -of-care.  
 
Rescue Therapy.  If subject  symptoms significantly worsen dur ing the course of the trial and are 
not controlled by increased steroid doses (high dose prednisone) , the subject  can receive PLEX 
or IVIg as a rescue therapy. PLEX  and IVIg  treated subject s would remain in the study and be 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 23 of 77 included in data analysis. The r ationale for this is that these subject s would have already been up  
titrated to a high prednisone dose but failed to adequately respond. Subject s that could not be 
managed with steroids , IVIg, or  PLEX and required additional immunotherapy (e.g., pulse IV 
steroids , azathioprine , etc. ) would be considered treatment failures  and potentially drop out of the 
study .  
  
Pyridostigmine . Subject s on pyridostigmine must be on a stable dose of ≤480 mg/day for a 
minimum of 2 weeks prior to the Screening Visit.  Subject must remain on a stable fixed dose for 
the duration of the study.  The dose cannot be changed after study entry.   
 
Note: Subjects o n pyridostigmine should be instructed to hold their medication for a minimum of 
12 hours prior to the Baseline Visit and all subsequent C linical Study Visits.   
 
Assessments.  Subject s will have clinical evaluations at baseline and then every 4 weeks 
therea fter (week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52) completed by a blinded evaluator 
(refer to SOA) .  Evaluations must be completed within +/ - 3 days of scheduled assessment.  The 
dose of prednisone will be recorded by each subject  daily and collected at each scheduled 
evaluation. Post -intervention status will be assessed by measuring MGFA, MGC, QMG, MG -ADL 
and MG -QOL scores. Blood will be collected for safety, specialized and other  studies at scheduled 
time points (refer to SOA tab le). Adverse effects will be monitored at each visit to assess safety 
and tolerability in this subject  population per Genentech and DAIT’s guidelines.  Please see  SOA 
and Section 6.4.5  for details pertaining to assessments done at the optional off-intervention  follow -
up visits at Weeks 72 and 96.  
 
Outcome Measures.  We will assess both the safety and steroid -sparing effect of rituximab in MG. 
The primary clinica l endpoint, steroid sparing effect, will be measured by determining the 
percentage of subject s achieving a ≥ 75% mean daily prednisone dose reduction and with clinical 
improvement or no significant worsening of symptoms  in the last 4 weeks of the study (weeks 49 -
52).   
 
MGC, QMG, MG -ADL and MG -QOL scales will be completed at each clinic visit and determine 
changes.     
 
Laboratory Assessments , Safety monitoring, serology testing, and specialized blood work will be 
obtaine d at the Screening Visit , Baseli ne Visit, Week 24 Visit, Week  52 visit  and any Unscheduled  
Visits . All these labs will  be centrally analyzed.  Th ese include : 
• Standard bloods: comprehensive metabolic panel, uric acid, LDH and CBC with platelets 
and differential  (Screening , Week 52  and Unscheduled ).   
• HbA1C  will be measured  (Screening  and Week 52) . 
• Serology testing: HBV, HCV, HIV  (Screening).  
• Specialized bloods:  AChR antibody titer , Total IgG, IgA and IgM levels , Flow c ytomet ry 
to assess B cell count  (Baseline, Week 24 , Week 52  and Unscheduled ).   
NOTE – Specialized bloods should be drawn prior to daily prednisone dose.  
• Mechanistic Bloods  (Baseline, Week 24 , Week  52 and Unscheduled ). 
 
**Note** Specialized and Mechanistic Biomarker blood work wi ll also  be done at the optional off -
intervention follow -up visits at Weeks 72 and 96. For more details, please refer to section 6.4.7 . 
 
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 24 of 77 Infusion Labs (complete metabolic panel, uric acid, LDH and CBC with platelets and differential) 
will be collected at each infusion visit and analyzed at each institution’s local laboratory prior to 
study drug infusion.   
 
A complete listing of Laboratory Assessments is included in Section 6.3.6  
 
Optional o ff-intervention follow -up. A lim ited clinical assessment will be completed during the 
optional observational off -study  intervention period at weeks 72 and 96 . Evaluations for these 
visits, if the subject is willing to participate, must be completed within /+ /-30 days of scheduled 
assessment.  Procedures include physical exam, outcomes assessments and blood collection. 
For more details regarding what is required to be done and collected, please refer to the SOA  and 
section 6.4.5 . 
 
**Note**  As the primary focus of the two additional optional observational time points is to 
assess B cell recovery/repopulation as a safety measure,  subject s who have received treatment 
with rituximab , or have  been involved with other interventions that result in Bcell depletion  since 
completion of the trial (i.e. Week 52) will be excluded from the o ptional off -intervention follow -up 
visits . 
4 SELECTION AND ENROLLMENT OF SUBJECTS  
4.1 Inclusion Criteria  
 
Subject  selection will be based on a diagnosis of MG and the following specific criteria:  
 
1. Subject s 21 to 90 years old  
2. Subjects must have generalized MG, defined as MGFA clinical classification grades 
2 (mild), 3 (moderate), or 4 (severe, but not intubated) at th e time of 
screening/randomization.  
3.  Elevated AChR antibody titer  
4. Subject ’s signs and symptoms should not be better explained by another disease 
process.  
5. Subjects must be on a stable standard immunosuppressive regimen:  
a. Prednisone only:  Prednisone dose must be at least 15mg/day (or the equivalent 
on alternate days), and the dose of prednisone must have been stable for at least 
4 weeks (28 days) prior to the baseline visit.  
b. Prednisone plus another immunosuppressive therapy (IST).  Immunosuppressive 
therapies other than prednisone, such as azathioprine, mycophenolate mofetil, 
cyclosporine, tacrolimus or methotrexate, are permitted, but the dose must have 
been stable for at least 6 months prior to the baseline visit.   
(Note: The pre dnisone dose must be stable as defined in the prednisone only 
group.  The IST dose must remain stable throughout the course of the study).  
6. Subject s must be willing to complete the study and return for follow -up visits.  
7. No history of thymoma, tumor, infectio n, or interstitial lung disease on chest CT, MRI, 
or chest x -ray. Note: Chest x -ray will be  completed at screening to look of interstitial 
lung disease.  A chest CT or MRI to evaluate for thymoma must have been 
completed as part of prescreening.   
8. Able and  willing to give written informed consent and comply with the requirements 
of the study protocol . 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 25 of 77 9. Subject s must to able to give written informed consent before participating in this 
study. A copy of the signed consent must be kept in the subject ’s medical record.  
10. Men and women of reproductive potential must agree to use an acceptable method 
of birth control during treatment and for twelve months (1 year) after completion of 
treatment . 
4.2 Exclusion Criteria  
 
Disease Specific Exclusion Criteria  
 
1. A history of chr onic degenerative, psychiatric, or neurologic disorder other than MG 
that can produce weakness or fatigue.  
2. Other major chronic or debilitating illnesses within six months prior to study entry.  
3. Female subject s who are premenopausal and are:  
(a) pregnant on  the basis of a serum pregnancy test,  
(b) breast -feeding, or  
(c) not using an effective method of double barrier (1 hormonal plus 1 barrier method 
or 2 simultaneous barrier methods)  or birth control (birth control pills, male condom, 
female condom, intra uterine device, Norplant, tubal ligation, or other sterilization 
procedures).  
4. Altered levels of consciousness, dementia, or abnormal mental status.  
5. Thymectomy in the previous six months.  
6. Subject s who have been medicated with immunosuppressive drugs not lis ted in 
inclusion #5 within the last 8 weeks (56 days)  prior to the baseline visit . 
7. Subjects who have been medicated with an immunosuppressive agent such as 
azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus or methotrexate , that 
is withdrawn within 8 weeks (56 days) of the Baseline Visit.  
8. Subjects who have received IVIg or PLEX treatment within the last 4 weeks (28 
days) prior to the baseline visit.   
9. Unstable dose  or a stable dose of > 480 mg/day  of pyridostigmine  in 2 weeks prior to 
screening visit  
10. Daily use of non -steroidal anti -inflammatory drugs (NSAIDs).  
11. History of renal or hepatic insufficiency or elevated liver enzymes  (AST or ALT >2.5 x 
Upper Limit of Normal ). 
12. History of bone marrow hypoplasia, leucopenia, thromb ocytopenia, significant 
anemia, clinical or laboratory evidence of immunodeficiency syndromes , that are not 
transient events or side effects related to a clinical procedure (i.e. plasmapheresis) 
and within one year of screening.  
13. Forced Vital Capacity (FVC)  <50% of percent predicted.  
 
General Safety & Laboratory Exclusion Criteria  
 
14. ANC < 1.5 x 103  cells/microliter  
15. Hemoglobin:  < 8.0 gm/dL  
16. Platelets:  < 100,000/mm  
17. Positive Hepatitis B or C serology (Hep  B surface antigen and Hep C antibody)  
18. History of positive HIV (HIV conducted during screening if applicable)  
19. Treatment with any investigational agent within 4 weeks of screening or 5 half -lives 
of the investigational drug (whichever is longer)  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 26 of 77 20. Receipt of a live vaccine within 4 weeks prior to randomizati on 
21. Previous t reatment with rituximab (MabThera ® / Rituxan ®) 
22. Previous treatment with natalizumab (Tysabri ®) 
23. History of severe allergic or anaphylactic reactions to humanized or murine 
monoclonal antibodies  
24. History of recurrent significant infection or histo ry of recurrent bacterial infections  
25. Known active bacterial, viral fungal mycobacterial, or other infection (including 
tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail 
beds) or any major episode of infection requiring  hospit alization or treatment with IV  
antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to 
screening  
26. Unstable steroid dose in the past 4 weeks  (28 days)  
27. Lack of peripheral venous access  
28. History of drug, alcohol, or chemical a buse within 6 months prior to screening  
29. Concomitant malignancies or previous malignancies, with the exception of 
adequately treated basal or squamous cell carcinoma of the skin or  carcinoma in situ 
of the cervix  or prostate . 
30. History of psychiatric disorder  that would interfere with normal participation in this 
protocol  
31. Significant cardiac or pulmonary disease (including obstructive pulmonary disease)  
32. Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding giving reasonable suspicion of a disease or condition that 
contraindicates the use of an investigational drug or that may affect the interpretation 
of the results or render the subject  at high risk from treatment complications   
33. Subjects that do not record daily prednisone doses for at least 28 days before the 
Baseline Visit, or subjects whose prednisone dose varies by ≥6mg/day on average.  
34. Prednisone dose of more than  100 mg/day  (or 200 mg over a two d ay period ). 
 
4.3 Subject Withdrawal Criteria  
 
If subject  symptoms significantly worsen during the course of the trial and are not controlled by 
increased steroid doses (high dose prednisone) , the subject  can receive PLEX or IVIg as a rescue 
therapy. PLEX  and IVIg  treated subject s would remain in the study and be included in data 
analysis. The rationale for this is that these subject s would have already been up  titrated to a high 
prednisone dose but  failed to adequately respond. Subject s that could not be managed with 
steroids , IVIg, or  PLEX and required additional immunotherapy (e.g., pulse IV steroids , 
azathioprine, etc. ) would be considered treatment failures  and likely withdrawn from the study .  
 
Sample size has been determined to include a 20% subject withdrawal rate and will not replace 
subjects.   
 
Subjects that exhibit serious adverse effects will be reviewed by the safety monitoring board to 
determine if removal from the study is necessary.  
4.4 Study Enrollment Procedures  
 
The informed consent will be obtained by study team member  at the Screening Visit or  up to 1 
week (7 days) prior .    
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 27 of 77 4.4.1  Subject Recruitment and Retention  
 
Participants will be recruited from clinics at participating NeuroNEXT Network sites. Postings will 
be placed on www.neuronext.org , www.myasthenia.org , www.mda.org ,  
www.ninds.nih.gov/disorders/clinical_trials ,and other disease specific websit es. Flyers about the 
study will be sent to community neurologists at NeuroNEXT clinical sites. Webinars will be 
conducted for participant recruitment as needed.  Interested participants will be contacted by the 
investigators or their staff and invited to par ticipate. These recruitment strategies will include a 
mechanism by which the subject s can provide their contact information. We will use the 
NeuroNEXT Recruitment and Retention Committee to identify recruitment strategies.   If 
recruitment is slower than ex pected and specific enrollment targets are not reached, we plan to 
activate additional NeuroNEXT sites.  
4.4.2  Screening Logs  
 
Screening logs to document reasons for ineligibility and reasons for nonparticipation of eligible 
subjects will be stored centrally at t he NeuroNEXT Data Coordination Center.  
 
Sites will be instructed to complete EDC based pre -screening logs for all pre -screened patients 
that meet the following criteri a:  generalized AChR positive MG AND  on prednisone.  
4.4.3  Informed Consent  
 
Written informed consent will be obtained from each study participant before any study -specific 
procedures or assessments are done and after the aims, methods, anticipated benefits, and 
potential hazards are explained. The participant’s willingness to part icipate in the study will be 
documented in writing in a consent form approved by the NeuroNEXT Central Institutional Review 
Board (CIRB), which will be signed by the participant with the date of that signature indicated. 
The site will keep the original con sent forms and a copy will be given to the participant. It will also 
be explained to the participant that they are free to refuse entry into the study and free to withdraw 
from the study at any time without prejudice to future treatment. Written and/or ora l information 
about the study in a language understandable by the participant will be given to all participants.  
 
Written informed consent will  also be obtained from each study participant  prior to proceeding 
with and performing all procedures at the  optio nal Week 72 and Week 96 Visits. A separate 
consent form wil l be provided by the study team, which will be used to document the subject’s 
willingness to participate in the off study -intervention  follow -up visits. All the requirements outlined 
above also apply to this secondary consent form and consent process.  Subjects may be 
consented prior to Week 52 or at Week 72 prior to any study -related procedures being performed.  
If the Week 72 window has passe d for any given subject, but they are willing to coming  for Week 
96, they can be consented at Week 96 prior to any procedures being performed.  
4.4.4  Subject Prednisone Diary  
 
Subjects will be provided a daily prednisone diary at the Screening Visit.  Subjects will be 
instructed how to fill out the diaries for accura te recording of dosage for prednisone .  These will 
be collected, reviewed and information recorded at each scheduled visit, including the baseline 
visit.  Compliance with prednisone diary completion will be monitored at each visit.  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 28 of 77 Prednisone Diaries do n ot need to be collected at the extended follow -up visits at Weeks 72 and 
96.   
 
4.4.5  Randomization/Treatment Assignment  
 
Randomization will be performed through an interactive website, and  will be stratified based on 
the steroid dose at baseline, moderate dose prednisone (15 -35 mg/day) and high dose 
prednisone (>35 mg/day), as well as standard of care treatment regimen at the baseline visit.  
Subjects will be assigned a study ID at the time  of enrollment.  The study ID includes the 
identification of the center and a unique subject ID.  The DCC will generate a randomization table 
for each of the strata using a permuted block design with random block sizes.  
5 STUDY INTERVENTIONS/STUDY MEDICATION /STUDY DRUG OR DEVICE  
5.1 Study Medications/Interventions, Administration, and Duration  
 
Genentech, Inc . will provide rituximab (Rituxan ®) and matching placebo labeled for 
investigational use. The NeuroNEXT central pharmacy, the Clinical Materials Services Uni t 
(CMSU) at the University of Rochester Medical Center (URMC) will create active and placebo 
study drug kits with unique identifiers not associated with the randomization ID . Each kit will 
contain 12 of the 100mg/10ml vials of the Rituxan ® or matching plac ebo and four (4) of the 
500mg/50ml vials of the Rituxan ® or matching placebo.  Each kit is good for 1 full cycle of dosing 
(4 infusions over the course of 4 weeks) of study drug assuming a maximum dose of 
800mg/weekly dose.  Each subject will receive a tot al of 2 full kits to allow for 2 full cycles of 
dosing. The CMSU will provide each approved site with an appropriate number of active and 
placebo kits to support subjects enrolled at the site. CMSU will prepare  and dispense both study 
drug and placebo control.  The Protocol PI will ensure maintenance of complete and accurate 
records of the receipt, dispensation, and disposal or return of all study  drug in accordance with 
Title 21 Code of Federal Regulations (C.F .R.), Part 312.57 and 312.62 and Genentech 
requirements.  
 
Rituximab is a highly purified, 1328 –amino acid antibody with an approximate molecular mass of 
145 kD.  The chimeric mouse/human anti -CD20  antibody is a glycosylated IgG1  
immunoglobulin containing  murine light and heavy chain variable regions and human 1 heavy 
chain and  light chain constant regions . 
 
Rituximab will be administered intravenously (IV) at 375mg/m2 weekly consecutively for four 
weeks and then repeated at six months . To prevent infus ion-associated reactions, each subject 
will be administered premedication with 1000 mg oral acetaminophen and 50 mg oral 
diphenhydramine within 30 to 60 minutes prior to each rituximab infusion. If subject has an 
infusion related reaction, the subject will receive 100 mg methylprednisolone IV 30 minutes prior 
to the next infusion.  If the subject tolerates this infusion than methylprednisolone premedication 
would not be offered at next infusion.   Subjects will  be administered rituximab  by staff  and at an  
infusion center  experienced with this medication.   Refer to section 5.2 for additional specific 
details.  
 
The most common side effects are infusion -related symptoms, particularly with the first rituximab 
infusion.   These symptoms include flu -like symptoms, fever, chills/rigors, nausea, urticaria, 
headache, bronchospasm, angioedema, and hypotension.   Since hypotension may occur during 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 29 of 77 Rituximab infusion, consideration should be given to withholding antihypertensive medications 12 
hours prior to an d throughout the r ituximab infusion.   The decision to hold antihypertensive 
medications  will be based on  the discretion of local site investigator.   Angina pectoris or cardiac 
arrhythmias, such as atrial flutter  or fibrillation, have occurred in subject s treated with rituximab. 
Therefore, cardiac monitoring will be performed during and after all infusions  (immediate post -
infusion period) for subject s with a history of cardiac disease. In the pooled, placebo -controlled 
studies, the proportion of patients wi th serious cardiovascular reactions was 1.7% and 1.3% in 
the rituximab  and placebo treatment groups, respectively. In rare instances, severe and fatal 
infusion -related reactions have occurred.    
 
Progressive multifocal leukoencephalopathy (PML) is the most significant potential complication, 
however, the relative risk is thought to be low  in HIV negative subjects based on a recent review.40 
The incidence is < 1 per every 10,000 patients treated with rituximab.   It is reassuring that no 
cases of PML have been reported in the rituximab MG population.  We plan to minimize 
concomitant immunosuppressive therapies in our subjects and enroll subjects who are only 
receiving standard of care MG treatment regimens.  We hav e defined these groups as subjects 
receiving either only prednisone or prednisone plus only one IST.  Please refer to eligibility criteria 
for specific details.  These regimens represent real world scenarios and are also consistent with 
the types of patien ts included in our pilot study where no significant safety concerns were 
observed7. We recommend careful review of immunotherapy regimen for every subject prior to 
initiating rituximab and to limit use of rituximab treatment to the groups as defined above as 
combined treatments could pose a higher PML risk. Refer to the manufacture Investigator’s 
Brochure for additional details.  Subjects who are on prednisone plus one other IST, will continue 
to have routine safety monitor ing as per standard of care practices specific to that IST.  This 
monitoring will be conducted by treating the physician.    
5.2 Handling of Study Medication s/Intervention s 
 
Overview.   Rituximab is formulated for IV administration as a sterile product in 9.0  mg/mL sodium 
chloride, 0.7  mg/mL polysorbate 80, 7.35  mg/mL sodium citrate dihydrate, and Sterile Water for 
Injection (pH  6.5).  Rituximab is a sterile, clear, colorless, preservative -free liquid concentrate for 
intravenous (IV) administration. Rituximab is  supplied at a concentration of 10 mg/mL in either 
100 mg (10 mL) or 500 mg (50 mL) single -use vials  and will be reconstituted for infusion by the 
site’s investigational drug  pharmacy in  0.9%NaCl or D5W . Local pharmacists should refer to the 
Study Drug Package Insert provided to obtain guidance on  the dilution of Rituximab, and follow 
the institutional policies for the specific dilution ratio.  
 
Placebo will be provided by Genentech and is a sterile product in 9.0  mg/mL sodium chloride, 
0.7 mg/mL polysor bate 80, 7.35  mg/mL sodium citrate dihydrate, and Sterile Water for Injection 
(pH 6.5).  Placebo will be reconstituted for infusion by the site’s investigational drug pharmacy or 
appropriately trained designee for IV administration as a sterile product of 0.9%NaCl or D5W.   
 
To prevent infusion -associated reactions, each subject will be administered premedication with 
1000 mg oral acetaminophen and 50 mg oral diphenhydramine within 30 to 60 minutes prior to 
each rituximab infusion. If subject has an infusio n related reaction, subject will receive 100 mg 
methylprednisolone IV 30 minutes prior to the next infusion.  If subject tolerates this infusion than 
methylprednisolone premedication would not be offered at next infusion.    Premedications will be 
stored a t each local pharmacy and prepared by the local pharmacist.   
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 30 of 77 Stora ge and Stability .   No preservative is used in rituximab; therefore, the vials are intended for 
single use only.  Rituximab is biologically and chemically stable at 2 C–8C (36F–46F). Do not 
use rituximab vials beyond the expiration date stamped on the drug packaging  and p rotect the 
drug from direct sunlight. Rituximab solutions for infusion, once diluted, may be stored at 2 C–
8C (36F–46F) for 24  hours and at room temperature (23 C) for an additional 24  hours.  
However, since Rituximab solutions do not contain preservative, diluted solutions should be 
stored refrigerated (2 C–8C).  No incompatibilities between rituximab and polyvinyl chloride or 
polyethylene bags have been observ ed.  A temperature monitoring log is to be maintained at all 
sites to record temperature on an at least daily basis.  
 
5.2.1  Preparation of Rituximab for Administration    
 
The dose of Rituximab should be based on the subject’s  Body Surface Area (BSA), calculated  
per local institution  procedures , and the amount to be infused should be calculated for a dose of 
375 mg/m2 for each infusion.  For more details, please refer to the NN103 Drug Dispensing 
System Users Manual  and Site Pharmacy Manual . 
   
Note: The weight recorded at Baseline Visit should be used for the first Infusion Cycle  
(Infusion s1-4) and the weight recorded at Week 24 Visit should be used for the second Infusion 
Cycle  (Infusion s 5-8). 
 
Rituximab should be given as a slow intravenous infusion.  It should not be administered as an 
intravenous push or bolus.  Premedi cation as noted in Section 5.1 is required  before each 
infusion.  Although rituximab may be administered on an outpatient basis, subject s may be 
hospitalized for observation at the discretion of the investigator.  Irrespective, rituximab should 
be administered in a hospital environment where full resuscitation facilities are immed iately 
available and under close supervision of the investigator or Safety assessor. Caution should be 
exercised when administering rituximab to subject s with a history of asthma.   Rituximab  should 
only be administered by a healthcare professional with appropriate medi cal support to manage 
severe infusion r eactions that can be f atal if they occur.   
 
Since hypotension may occur during rituximab infusion, consideration should be given to 
withholding antihypertensive medications approximately 12 hours prior to and throughout  the 
rituximab infusion. This will be completed at the discretion of local site investigator.   
 
First Infusion  (Infusion 1 only) : Initiate infusion at a rate of 50 mg/hr.  In the absence 
of infusion to xicity, increase infusion r ate by 50 mg/hr in crements every 30 minutes, to a  
maximum of 400  mg/hr. 
 
Subsequent Infusions  (Infusions 2 -8):  Initiate infus ion at a rate of 100 mg/hr.  In the  
absence  of infusion toxicity, increase rate by 100 mg/hr increments at 30-minute 
intervals, to a maximum of 400  mg/hr. 
 
If a hypersensitivity (non -IgE-mediated) or an infusion reaction develops,  the infusion rate 
should be reduced to half that rate, i.e. from 100 mg/h to 50 mg/h.  Subjects who experience a 
moderate to severe infusion related reaction (fever, chills, or hypotension) should have their 
infusion interrupted immediately and should receive aggressive symptomatic treatment.  The 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 31 of 77 infusion should not be restarted before all the symptoms have disappeared and then the 
infusion can continue at one -half the previous rate.  
 
Immediate infusion related reactions can occur with either p lacebo or rituximab treatment.   
 
After the end of infusion, the intravenous line should remain in situ for at least 1 hour in order to 
be able to administer drugs intrave nously if necessary. If there are no adverse events during 
this period of time, the intravenous line may be removed.  
 
For further details, including further management of infusion reactions, see the Investigator 
Brochure and the Rituxan  Package Insert.  
5.2.2  Vital Sign Collection and Infusion Monitoring  
 
Vital signs and monitoring for infusions reactions will be performed per standard practices of the 
local infusion center.  For purposes of this study, vital signs will be measured and recorded at a 
minimum of every 15 minutes for the first hour, then every 30 minutes until completion of the 
rituximab infusion.  Pulse oximetry will be obtained at baseline and as needed for symptoms of 
dyspnea .   
 
Cardiac monitoring will be performed during and after all infusion s of rituximab for subject s who 
develop clinically significant arrhythmias, or who have a history of arrhythmia or angina.  
5.2.3  Local Labs Prior to Infusion  
 
Lab panels will be drawn and analyzed locally  up to 1 day  prior to initiation of study drug infusion.  
Lab panels will include complete metabolic panels (including LFT and GFR calculation), uric acid, 
LDH and CBC with differential (including ANC).  These labs will be reviewed by the site 
investigator to ensure that there are no contraindications to infusio n.   
5.3 Study Drug Accountability  
 
In accordance with local regulatory requirements, the investigator, designated site staff, or head 
of the medical institution (where applicable) must document the amount of investigational product 
dispensed and/or administered to study subjects, the amount  received from the central pharmacy, 
and the amount destroyed upon completion of the study. Each site  investigator is responsible for 
ensuring product accountability records are maintained throughout the course of the study.   The 
designated unblinded pharm acist will keep drug inventory and accountability logs.  The inventory 
will include details of rituximab received and dispensed to subjects, batch, and ID numbers. All 
unused vials must be kept until reconciliation of delivery records with accountability l ogs by the 
monitor. After the monitor has performed accountability, the site will be instructed by the CCC or 
designee to either destroy the remaining study medication/device or return it to the Central 
Pharmacy or manufacturer. An accounting must be made of any drug deliberately or accidentally 
destroyed. Discrepancies between the amount of  rituximab received and dispensed drug must be 
reconciled.  
 
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 32 of 77 5.4 Concomitant Interventions  
 
Subjects will be on either prednisone only or prednisone plus another IST  at time  of enrollment .  
Subjects who are on prednisone plus one other IST, will continue to have routine safety 
monitoring as per standard of care practices specific to that IST.  This monitoring will be 
conducted by the treating  physician.  The dose of IST must remain stable throughout the course 
of the study  (i.e. through week 52) .   Subjects who are on pyridostigmine (≤ 480 mg/day) at the 
time of enrollment must remain on a stable dose throughout the course of the study, and cannot 
be chang ed.  
 
These requirements are not applicable to the optional off-intervention  follow -up visits. During 
this time subjects will be treated per best medical practice (standard of care) for their MG at the 
discretion of the treating physician. However, a s the primary focus of the two additional optional 
observational time points is to assess B cell recovery/repopulation as a safety measure,  
subjects who have received treatment with rituximab, or have been involved with other 
interventions that result in b cell depletion since completion of the trial (i.e. Week 52) will be 
excluded from the optional off -intervention follow -up visits.  
 
For more details please refer to section 6.4.5 . 
 
 
5.5 Subject compliance  
 
Subject compliance with study intervention (rituximab) will be directly monitored at the infusion 
center.  Subjects will complete a daily prednisone dose log that will be collected and reviewed 
every 4 weeks to monitor steroid compliance during the study.  
 
6 CLINICAL AND LABORATORY EVALUATIONS/STUDY PROCEDURES
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 33 of 77 6.1 Schedule of Activities (SOA)  – on-intervention period (Screening – Week 52 ) 
Visit Windows +/ - 3 days for Week s 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.  Cycle 1 Infusion Visits will take place weekly beginning at Week 0 through Week 3. Cycle 2 Infusion Visits will take 
place beginning at Week 24 through Week 27  (See Section 6.3.3 for timing of visits)  
 Screening 
Visit Day 0  Week 
0 Wk 1  Wk 2  Wk 3  Wk 
 4 Wk  
8 Wk 
12 Wk 
16 Wk 
20 Wk 
24 Wk 
24 Wk 
25 Wk 
26 Wk 
27 Wk 
28 Wk 
32 Wk 
36 Wk 
40 WK 
44 Wk 48  Wk 52  
Unsc
hedul
ed   (-4 - 6 wk) Baselin
e Infusio
n 1 Infusio
n 2 Infusio
n 3 Infusio
n 4       Infus
ion 5 Infus
ion 6 Infus
ion 7 Infus
ion 8        
Informed 
Consent  X                        
Randomization   X                       
Demographics  X                        
Medical History  X                        
Physical Exam  X X     X X X X X X     X X X X X X X X 
Concomitant 
Medication  X X X X X X X X X X X X X X X X X X X X X X X X 
Vital Signs  X X     X X X X X X     X X X X X X X X 
Pregnancy 
Testinga X X X X X X       X X X X         
Standardized 
Bloodsb X                      X X 
HbA1C  X                      X  
Serology Testing 
(HBV,HCV, HIV)  X                        
Rituximab 
Infusionsc   X X X X       X X X X         
Infusion Labsc   X X X X       X X X X         
Specialized 
Bloods d  X          X           X X 
Mechanistic 
Bloods   X          X           X X 
MGC Score  X X     X X X X X X     X X X X X X X X 
QMG Score   X     X X X X X X     X X X X X X X  
MG-ADL Score  X X     X X X X X X     X X X X X X X  
MG-QOL Score  X X     X X X X X X     X X X X X X X  
Prednisone Dose 
Adjustments        Xe X X X X X     X X X X X X X Xg 
Daily Steroid 
Diary Information  Xf X     X X X X X X     X X X X X X X X 
AE Review/ 
Safety 
Monitoring   X X X X X X X X X X X X X X X X X X X X X X X 
EKG  X                        
Chest X -ray X                        
a – Serum pregnancy test at screening; urine pregnancy tests thereafter  
b – Standard bloods: Comprehensive metabolic panel, LDH, uric acid, CBC with platelets and differential  
c – Rituximab dose: 375mg/m2 IV (cycle 1: week1 -4; cycle 2: week 24 -27).  Infusion visit labs (comprehensive metabolic panel, LDH, uric acid,  CBC with platelets and differential) performed locally  
d – Specialized Bloods: 1. AChR antibody titer (Mayo Medical Laboratory, Rochester, MN). 2. Total IgG, IgA and IgM levels.  3. Ig G subclasses (1,2,3, 4) . 4. Flow Cytometry to assess B cell counts. N OTE – Specialized bloods should be drawn prior to 
daily prednisone dose.  
e – Prednisone dose may be increased at this visit per Site Investigator judgment  in cases of clinical worsening .  Forced taper begins at Week 8 based on steroid taper protocol.  
f – Subjects will be instructed on how to fill out the diaries for accurate recording of dosage for prednisone only. Subjects will  record their daily prednisone dose on a Daily Prednisone Diary beginning the day after the Screening Visit.  The diary will b e 
recorded in the EDC starting at the Baseline Visit and every visit thereafter.  
g – Prednisone dose may be evaluated and increased at the Unscheduled Visit per Site Investigator judgment in cases of clinical w orsening. Prednisone tapering should not occur at U nscheduled Visits that occur after Week 8. If the Site Investigator 
feels that it is clinically necessary to taper at the visit, the study team must be consulted and provide approval for doing so.  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 34 of 77 6.2 Schedule of Activities (SOA)  – optional off-intervention period (Weeks 72 and 96)  
 
Visit Windows +/-30 days for Weeks 72 and 96  
 Wk 72  Wk 96  
   
Informed Consenta X  
Randomization    
Demographics    
Medical Historyb X X 
Physical Exam  X X 
Concomitant 
Medicationc X X 
Vital Signs  X X 
Pregnancy Testing    
Standardized Bloods    
HbA1C    
Serology Testing 
(HBV,HCV, HIV)    
Rituximab Infusions    
Infusion Labs    
Specialized Bloodsd  X X 
Mechanistic Bloods  X X 
MGC Score  X X 
QMG Score    
MG-ADL Score  X X 
MG-QOL Score  X X 
Prednisone Dose 
Adjustments    
Daily Steroid Diary 
Information    
AE Review/ Safety 
Monitoringe X X 
EKG    
Chest X -ray   
 
**Note** Subjects who have received treatment with rituximab, or have been involved with othe r 
interventions that result in B  cell depletion since completion of the trial (i.e. Week 52) will be excluded 
from the optional off -intervention follow -up visits.  If there’s a plan or interest by the treating physician to 
utilize rituximab clinically as part of the disease management str ategy for a given subject prior to the 
Week 72 or 96 Visits, the study team should be notified and all efforts should be made to bring the 
subject in prior to receipt of rituximab in order to capture long -term follow -up data.  
 
a – Written informed consent  will also be obtained from each study participant prior to proceeding with and 
performing all procedures at the optional Week 72 and Week 96 Visits. Subjects may be consented prior 
to Week 52 or at Week 72 prior to any study -related procedures being perfo rmed.  
b – Medical History will be updated at these two visits  to record only any autoimmune disease(s) that the 
subject has been diagnosed with since the previous visit . 
c – MG-related medication, including prednisone dose and/or any changes if applicable will be recorded.  
Additionally,  any immunosuppressive  therapies and steroids taken for other diseases will also be 
recorded.  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 35 of 77 d – Specialized Bloods: 1. AChR antibody titer (Mayo Medical Laboratory, Rochester, MN). 2. Total IgG, 
IgA and IgM levels.  3. IgG subclasses (1,2,3, 4) . 4. Flow Cytometry to assess B cell counts. NOTE – 
Specialized bloods should be drawn prior to daily prednisone dose.  
e – At the Week 72 and 96 Visits, only those adverse events, serious and non -serious, that in the opinion 
of the In vestigator are deemed related  to study procedures will be reported, given that the subject has 
consented to the optional off -intervention follow -up visits. Additionally , any MG relapses  requiring rescue 
therapy that have occurred since the last visit will also be recorded.  
 
6.3 Study Staffing  
 
A blinded Clinical E valuator will be required to perform the outcome assessments (QMG, MGC, 
MG-QOL, and MG -ADL) and attend the Investigator's Meeting for training. The Clinical Evaluator 
may be a MD, RN, PA, PT, NP, or other health professional.   This individual may not be directly 
involved in reviewing adverse events.   
 
The principal investigator or a co -investigator (considered “treating physicians”) will perform the 
following procedures:  
 
• Medical history  
• Physical examination including assigning a MGFA MG grade.   
• Prednisone dose adjustment beginning at week 8.   
• Determination of worsening of MG symptoms.  
• Review of adverse events and concomitant medications  
 
The study coordinator will perform the following:   
 
• Explain in detail how subjects will fill out the diaries  for accurate recording of dosage for 
prednisone  
• Collect and review daily prednisone dose diaries  
• Vital signs  including weight  
• Pregnancy test  for women of childbearing potential  
 
6.4 Timing of Study  Activities  
6.4.1  Screening  Evaluations and Procedures  
 
Subject s identified as a potential candidate will be appropriately consented prior to the initiation 
of any study related procedures.  The signing of consent constitutes the start of the study for a 
given subject.  
 
The following will be performed during the screening visit:  
 
• Subject s will undergo a complete physical and neuro logical  examination  
 
• Vital signs will be measured  
 
• Phlebotomy will be performed in order to analyze the following:  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 36 of 77 o Serum  Pregnancy  
o Standard Labs: Comprehensive metabolic panel, uric acid, LDH  and CBC with 
differential  
o HbA1C   
o Serology Testing: HBV, HCV, and HIV  
 
• Subjects will be provided with information about the HIV and Hepatitis testing prior to the 
blood draw.  Subjects will be referred for HIV and hepatitis post -test counseling and 
medical care at each institution if necessary.  
 
• A 2-view chest x-ray (poste rioranterior and lateral), and EKG will be obt ained to document 
baseline status.  Chest x -rays will be read by a local radiologist, and EKGs will be read 
locally by an internist/cardiologist  or any qualified physician . If a cardiologist /internist  is 
not available to do the read, it is recommended for the EKG to be remotely read , if 
possible based on the site’s current setup.  
 
Note: If the subject has had a chest x -ray done within 60 days prior to the Screening V isit, 
a repeat  will not be required at Screening, provided that the results from the previous chest 
x-ray are available  and unrevealing . The previous chest x -ray s ource document will be 
required.  
 
• Immunization status or need for the following vaccinations in advance of randomization 
will be completed:  tetanus, diphtheria, influe nza, pneumococcus polysaccharide, 
Varicella , measles, mumps, rubella (MMR) and hepatitis  B vaccines.   
 
Note: Any required vaccination/booster for a subject  must be given at least 28 days 
(4 weeks ) prior to the baseline/randomization visit .  Required immunizations should be 
determined based on a subject’s age and comorbidities and are per best medical practice 
standard.  
 
• MGC, MG -ADL and MG -QOL assessments will be completed . (Note: MG -QOL should be 
administered prior to other outcomes evalua tions.)  
 
• Women of child bearing potential will be instructed to take proper precautions to avoid 
pregnancy.  
 
• When inclusion/exclusion criteria are met, protocol eligibility and admission information 
consisting of demographic data including age, sex, past medical history, concomitant 
medications including prednisone dose, prior AChR  antibody titer  history , confirm ation of 
no history of thymoma  on each subject  will be documented.   Subject s will be instructed 
not to take pyridostigmine for at least 12 hours prior to the Baseline  Visit and each follow -
up visit.    
 
Note:  It is recommended that a  chest CT or MRI  source document (i.e. radiology report)  
be obtained to evaluate for thymoma during the  prescreening  process  to determine 
eligibility .  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 37 of 77 • Subjects will  be instructed to complete prednisone diaries  for accurate recording of 
dosag e.  These will be collected, reviewed  and information recorded at the Baseline 
Visit and each scheduled visit thereafter.  
 
• Concomitant medications will be recorded.  
 
6.4.2  Baseline Visit Evaluations and Procedures  
 
All screening evaluations to determine eligibility will be completed within 4 to 6 weeks of 
screening visit (refer to SOA for details).  All successfully screened subjects will be randomized 
into the study within 6 weeks.  
 
The following will be performed during the baseline visit:  
 
• Prednisone diaries will be reviewed to ensure that subje cts have maintained a stable 
prednisone dose during the 28 days before the Baseline Visit.  A stable dose is defined 
as a dose that does not  vary by ≥ 6mg per day on average.  
• All Eligibility Criteria will be reviewed and verified by the site investigator.  The site 
investigator will sign off on the eligibility confirmation form prior to the randomization of 
any subject.  
• Subjects will undergo a complete physical examination  
• Vital signs will be measured  
• Urine Pregnancy Test  
• Phlebotomy will be performed in ord er to analyze the following (Note: Subjects will be 
asked to hold their usual prednisone dose on the day of the visit. ): 
o Specialized bloods: AChR  antibody titer, Total IgG, IgA and IgM levels, IgG 
subclasses (1,2,3, 4), and Flow Cytometry to assess B cell counts   
▪ NOTE – Specialized bloods should be drawn prior to daily prednisone 
dose.  
o Mechanistic bloods (immune cell analyses)  
 
• Outcome Assessments:  MGC, QMG, MG-ADL and MG -QOL will be completed . (Note: 
MG-QOL should be administered prior to other outcomes evaluations.)  
• Adverse Events will be reviewed and recorded  
• Concomitant medications will be recorded.  
6.4.3  Infusion Visits  
 
Cycle 1 Infusion Visits will take place weekly beginning at Week 0 through Week 3. Cycle 2 
Infusion Visits will take place beginning at Week 24 through Week 27.  
 
Ideally, the t iming of Infusions 2 -4 would be  anchored to Infusion Visit 1 , such that:  
• Infusion 2 is 7 ( +/- 1) days from In fusion 1  
• Infusion 3 is 14 ( +/- 1) days from Infusion 1  
• Infusion 4 is 21 ( +/- 1) days from Infusion 1  
 
Ideally, the t iming of Infusions 6-8 would be anchored to Infusion Visit 5 , such that:   
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 38 of 77 • Infusion 6 is 7 ( +/- 1) days from Infusion 5  
• Infusion 7 is 14 ( +/- 1) days from Infusion 5  
• Infusion 8 is 21 ( +/- 1) days from Infusion 5  
 
Please refer to the Manual of Operations, Section X (Study Medication and Central Pharmacy) 
and the Visit Windows Report available in the EDC once the Baseline Visit is complete.  
 
Infusion 1 may take place the same day as the Baseline Visit and must take place within 3 days 
following the Baseline Visit.  
 
Infusion 5 may take place the same day as the Week 24 Visit and must take place within 3 days 
of the Week 24 Visit.  
 
If, for any r eason, an infusion is held during either of the two cycles, it can be postponed up to 
one week (7 days) after the original scheduled date.  
 
• If the delayed infusion is administered within that one week, the subsequent  infusion 
should take place within the original time window  in order to resume  the initial infusion 
schedule . For example, if Infusion 2 is delayed but administered < 7 days  after the 
scheduled date, Infusion 3 should be administered as originally planned and not 
delayed as well .  
 
**Note** Two  separate Infusions should not be scheduled on consecutive days.  There 
should be a minimum of one day in between infusions.   
 
• If an Infusion is delayed by one week (7 days), then all subsequent infusions should be 
delayed by that same amount. For example  if Infusion 2 takes place 14 days a fter 
Infusion 1, then Infusion 3 will take place 21 days after Infusion 1, and Infusion 4 will 
take place 28 days after Infusion 1.  
 
**Note** If the Infusion cycles are delayed, the 4th infusion must take place prior to the 
Week 4 Visit, and the 8th Infusion must take place prior to the Week 28 Visit. The visits 
may take place on the same day,  
 
• If an infusion is held and cannot be administered within one week (7 days) of the original 
scheduled date, then that Infusion will be skipped altogether  (this will be designated as 
“missed”) , and efforts should be made to administer all subsequent infusions as 
scheduled.  
 
• If the 1st infusion of either cycle (Infusion 1 or 5) cannot be administered as scheduled , it 
can be delayed up to one week  after the original date. Subsequent infusions will be 
anchored o n the new date of the first infusion  and will follow the  weekly  window 
described above. If the first infusion of the cycle cannot be administered within one 
week of the original  date,  then that Infusion will be skipped altogether (this will be 
designated as “missed”), The schedule will then resume with second infusion of that 
cycle (i.e. the second infusion and all subsequent infusions will be anchored to the 
original date of the  first infusion ).  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 39 of 77 The study team must be notified, consulted and provide approval, should the site PI feel that an 
Infusion be held or postponed.  
 
The following will be performed during the infusion visits:  
 
• Urine Pregnancy Test  
• Infusion Labs: Complete metabolic panel,  uric acid, LDH  and CBC with differential 
(analyzed locally up to 1 day prior to each infusion)  
• Adverse Events will be reviewed and recorded  
• Concomitant medications will be recorded.  
• Study drug infusions (detailed in section 5.2) 
 
6.4.4  Clinical Study Visits  
 
Study Intervention Follow -up Visits:  
 
The allowable time window for study visits is plus or minus 3 days for Week 4, 8, 12, 16, 20, 24,  
28, 32, 36, 40, 44, 48, and 52 visits.  
 
The following will be performed during each study visit:  
 
• Prednisone diaries will be collected and reviewed  
o Prednisone dose will be reviewed and adjusted at Week 4 and each visit thereafter.  
The forced prednisone taper will begin at Week 8 as per steroid taper protocol.  
• Subjects will undergo a complete physical  examination  
• Vital signs will be measured  
• Phlebotomy will be performed at week 24 and 52.  
• Outcome Assessments: MGC, QMG, MG-ADL and MG -QOL will be completed . (Note: 
MG-QOL should be administered prior to other outcomes evaluations.)  
• Adverse Events will be reviewed and recorded  
• Concomitant medications will be recorded.  
 
A Participation Survey will also be given to each subject at the Week 52 or last Study  Visit. This 
will be a brief survey consisting of five questions. The purpose of the questionnaire will b e to 
determine why the subject decided to participate in the study. The questions will ask how the 
subject initially heard of the study, why they chose to participate, and what motivated them to 
stay in the trial. This information will help to determine wh ich recruitment and retention efforts 
were the most effective.  
 
For procedures done at Unscheduled Visits, see section 6.3.11.  
 
6.4.5  Optional Observation al Off-Intervention Follow -up Visits:  
 
Weeks 72 and 96 Visits:  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 40 of 77 The allowable time window for study visits is 60days for Week 72 and 96 visits  (+/-30 days).  
These t wo additional optional time points at weeks 72 and 96 will be done to follow B cell recovery 
and long -term durability of response.  
 
Subjects will be consented prior to the initiation of any study related procedures  at these optional 
visits . Subject s will  also be instructed not to take pyridostigmine for at least 12 hours prior to the 
Baseline  Visit and each follow -up visit.    
 
 
The following will be pe rformed during each study visit:  
• Subjects will undergo a complete physical examination  
• Vital signs will be measured  
• Phlebotomy will be performed at week 72 and 96  (please refer to the SOA  and section 
6.4.7). 
• Outcome Assessments: MGC, MG -ADL and MG -QOL will be completed. (Note: MG -QOL 
should be administered prior to other outcomes evaluations.)  
• Medical history will be updated  at these two visits to record only any autoimmune 
disease(s) that the subject has been diagnosed with since the previous visit.  
• MG-related medication, including prednisone dose and/or any changes if applicable will 
be recorded.  Additionally, any immunosup pressive  therapies and steroids taken for other 
diseases will also be recorded.  
• MG relapse requiring rescue therapy will be recorded  
• Adverse Events , serious and non -serious, related to study procedures per site 
investigator, will be reviewed and recorded . 
 
**Note** Subjects who have received treatment with rituximab, or have been involved with other 
interventions that result in B cell depletion since completion of the trial (i.e. Week 52) will be 
excluded from the optional off -intervention follow -up visits. If there’s a plan or interest by the 
treating physician to utilize rituximab clinically as part of the disease management stra tegy for a 
given subject prior to the Week 72 or 96 Visits, the study team should be notified and all efforts 
should be made to bring the subject in prior to receipt of rituximab in order to capture long -term 
follow -up data.  
 
6.4.6  Outcome Evaluations  
 
A blinde d evaluator will be required to perform the outcome assessments (QMG, MGC, MG -
QOL, and MG -ADL) and attend the Investigator's Meeting for training. The Clinical Evaluator  
may be a MD, RN, PA, PT, NP, or other health professional.   This individual may not be  directly 
involved in reviewing adverse events.  
 
Myasthenia Gravis Composite (MGC).    
The MGC is a new end-point that has been  developed for MG.   Spec ific components of the 
QMG, MG-ADL, and muscle testing are combined to obtain  the MGC score.   This is a br ief 
assessment that takes approximately 10 minutes to complete.  
 
Quantitative Myasthenia Gravis (QMG).    
The QMG is a validated 13 -item test that objectively measures ocular, bulbar, extremity 
fatigue/strength, and respiratory function  (forced vital capacity) . A battery of quantitative 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 41 of 77 functional tests is completed from which a QMG score  is calculated . This assessment takes 30 -
40 minutes to administer . 
 
MG-Activities of Daily Living score (MG -ADL)  
This 8 point scale assesses the subject ’s ability to perform daily activities and can be performed 
in approximately 5 minutes.   
 
MG-Quality of Life (MG -QOL) score . 
The subject completes the 15 -question MG -QOL questionnaire and reports the effect of MG on 
their quality of life. The MG -QOL shoul d be administered prior to other outcomes evaluations at 
each visit.  
 
6.4.7  Laboratory Testing  
 
Safety labs will be drawn and analyzed locally the day before or at each infusion visit.  All other 
labs will be analyzed centrally and sent to CMSU  with the exception of the mechanistic labs 
which will be sent to Yale University.  
 
Subject s will be instructed not to take pyridostigmine for at least 12 hours prior to the Baseline  
Visit and each follow -up visit.    
 
Subjects are asked not to take their usual p rednisone dose on the day of the Baseline Visit, 
Week 24  Visit, and Week 52  Visit as well as any Unscheduled Visit  
 
Screening Visit:  
• Serum  Pregnancy  
• Standard Labs: Comprehensive metabolic panel, uric acid, LDH  and CBC with 
differential  
• HbA1C   
• Serology Testing: HBV, HCV, and HIV  
 
Baseline:  
• Urine Pregnancy (analyzed on site)  
• Specialized bloods: AChR antibody titer, Total IgG, IgA and IgM levels, IgG subclasses 
(1,2,3, 4), and Flow Cytometry to assess B cell counts   
• Mechanistic bloods (immune cell analyses)  
 
Note: Please remind subjects to hold their usual prednisone dose the day of the visit . 
 
Infusion 1 -4 
• Urine Pregnancy (analyzed on site)  
• Infusion Labs: Comprehensive metabolic panel, uric acid, LDH  and CBC with differential 
(analyzed locally up to 1 day prior to each infusion)  
  
Week 24  
• Specialized bloods: AChR antibody titer, Total IgG, IgA and IgM levels, IgG subclasses 
(1,2,3, 4), and Flow Cytometry to assess B cell counts   
• Mechanistic bloods (immune cell analyses)  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 42 of 77   
Note: Please remind subjects to hold their usual prednisone dose the day of the visit.  
 
Infusion 5 -8 
• Urine Pregnancy (analyzed on site)  
• Infusion Labs: Comprehensive metabolic panel, uric acid, LDH  and CBC with differential 
(analyzed locally up to 1 day prior to each infusion)   
 
Week 52  
• Specialized bloods: AChR antibody titer, Total IgG, IgA and IgM levels, IgG subclasses 
(1,2,3, 4), and Flow Cytometry to assess B cell counts   
• Standard Labs: Comprehensive metabolic panel, uric acid, LDH  and CBC with 
differential  
• HbA1C   
• Mechanistic bloods (immune cell analyses)  
 
Note: Please remind subjects to hold their usual prednisone dose the day of the visit.  
 
Unscheduled Visit  (if applicable)  
• Specialized bloods: AChR antibody titer, Total IgG, IgA and IgM levels, IgG subclasses 
(1,2,3, 4), and Flow Cytometry to assess B cell counts   
• Standard Labs: Comprehensive metabolic panel, uric acid, LDH  and CBC with 
differential  
• Mechanistic bloods (immune cell analyses)  
 
Note: Please remind subjects to hold their usual prednisone dose the day of the visit.  
 
Optional Observation Off -Intervention Follow -up Visits  (weeks 72 and 96) : 
• Specialized bloods: AChR antibody titer, Total IgG, IgA and IgM levels, IgG subclasses 
(1,2,3, 4), and Flow Cytometry to assess B cell counts   
• Mechanistic bloods (immune cell analyses)  
 
Note: Please remind subjects to hold their usual prednisone dose the day of the visit.  
 
6.4.8  Prednisone Dose Adjustments  
 
Subjects will be treated with a minimum oral prednisone dose of 15 mg/day or equivalent every 
other day until week 8.  Each subject’s prednisone dose will be evaluated at the Week 4 Visit .   
 
The prednisone dose cannot  be tapered at the Week 4 Visit. It should be  maintained at enrollment 
dose and only increased in cases of clinical worsening  (as determined by the MGC Score)  only, 
per the site investigator’s discretion.    
  
Forced Prednisone Taper  
 
A forced prednisone steroid taper will begin at the Week 8 Visit.  Dose adjustments are based on 
changes from the subject's baseline MGC score  and prior study visit .  The MGC score will be 
calculated, confirmed and available during the study visit in order to make steroid dose 
adjustment. Prednisone dose will be lowered at every 4 -week assessment beginning at the Week 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 43 of 77 8 Visit  following confirmation of clinical improvement or stable symptoms based on MGC score 
(current MGC score is not more than 2 points above the Baseline Visit or prior study visit MGC 
score) . 
  
Predniso ne will be tapered : 
❖ If the MGC score is no more than 2 po ints higher than the  Baseline Visit score AND  
❖ MGC score is n o more than 2 points above the P rior Study V isit score  
 
For subjects taking prednisone daily, the every 4 week  taper  schedule will be:  
 
Daily Prednisone Dose (mg)  Taper to Dose (mg):  
100 90 
90 80 
80 70 
70 60 
60 50 
50 40 
40 30 
30 20 
20 15 
15 10 
10 7.5 
7.5 5 
5 3 
3 2 
2 1 
1 0 
 
For subjects taking prednisone every other day , the every 4 week  taper  schedule will be:  
 
Every Other Day Prednisone Dose (mg)  Taper to Dose (mg):  
200 180 
180 160 
160 140 
140 120 
120 100 
100 80 
80 60 
60 40 
40 30 
30 20 
20 15 
15 10 
10 7.5 
7.5 5 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 44 of 77 Every Other Day Prednisone Dose (mg)  Taper to Dose (mg):  
5 2.5 
2.5 0 
 
Note: While typical maximum daily doses of prednisone will be 60 mg per day  (or equivalent on 
alternating days) , the above t able details a taper schedule with rows  shaded in grey if subjects 
enter the study on a higher dose.  The absolute maximum allowable prednisone dose at study 
entry is 100 mg per day  (or equivalent on alternating days).    
 
As subjects may be on a dose that is s lightly different than the above (i.e., 45 mg/day, 
alternating doses), the tapered dose will begin at the closest lower dose on the table and then 
follow tapering as per protocol.   Subjects taking more than 100 mg/day or 200 mg over a two 
day period  will b e excluded from the study.     
 
It is recommended that the Prednisone Dose Adjustment at Week 52 be done in the same 
manner as the other clinical study visits (i.e. tapered, maintained, or increased based on the 
subject’s MGC score) .  However, i f the site PI feels that it is in the best interest of the subject to 
deviate from the dose adjustment protocol (i.e., for safety related reasons for instance), this will 
be allowed . If the decision is to not adjust the prednisone dose per protocol at Week 52, please  
notify the study t eam prior to proceeding.  
 
Prednisone Dose Adjustment s in Case s of Clinical Worsening  
 
If the MGC score is 3 or more points higher than the Baseline Visit score : 
❖ The taper will be stopped and prednisone will be increased per the guidelines  below.   
 
If the MGC score is less than or no more than 2 points higher than the Baseline  Visit score, but 
has increased 3 or more points than the MGC score at the previous  Study  Visit: 
❖ The taper will be stopped and prednisone dose may be either  held or increased per study 
prednisone schedule. The decision to hold or increase the prednisone dose in this case is at 
the discretion of the Site Investigator.  
 
Note: The prednisone dose will be increased until symptoms are resolved or at least stabilized 
to baseline status (MGC score is the same or less than the Baseline  Visit score).  
 
The following schedule will be followed  for sub jects with clinical worsening and who  require the 
prednisone dose to be increased:   
• For subjects on > 15 mg daily or the equivalent for every other day dosing, it is 
recommended that the prednisone daily dose be initially increased by 20 mg.  
•  For subjects on ≤ 15 mg daily or the equivalent fo r every other day dosing, prednisone may 
be increased by 10 or 20 mg, at the physician’s discretion.   
• If the prednisone dose is up titrated, the maximum dose would be 60 mg/day even if the 
subject was on a higher dose at study entry.  
 
Once symptoms stabilize (MGC score is the same or less than the Baseline Visit score  and not 
more than 2 points above the prior study visit ), the prednisone taper can again be resumed per 
the above protocol at the next scheduled visit/assessment.  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 45 of 77 This is a forced stero id taper that is based on MGC score.  If the site investigator (treating 
physician) did not taper per protocol , this will be recorded as a  protocol deviation and will be 
corrected immediately .  As this is linked with primary outcome we wanted to make the decision 
on lowering the dose as objective as possible .  A mechanism will be put in place to double check 
the MGC score calculation made at the visit and whether or not prednisone adjustment decision 
was made correctly.   
 
6.4.9  Physical Exam  
 
A physical exam will be completed at the Screening Visit, Baseline Visit, weeks 4, 8, 12, 16, 20, 
24, 28, 32, 36, 40, 44, 48 and 52  Visits , as well as the optional  weeks 72 and 96  Visits .   
 
The physical exam will include assigning a  MGFA clinical classification grade. Th e grades are 
as follows:  
Class I - Any ocular muscle weakness, may have weakness of eye closure, all other 
muscle strength is normal.  
Class II – Mild weakness affecting other than ocular muscles, may also have ocular 
muscle weakness of any severity.  
Class III – Moderate weakness affecting other than ocular muscles, may also have 
ocular muscle weakness of any severity.  
IIIa. Predominantly affecting limb, axial muscles, or both. May also have lesser 
involvement of oropharyngeal muscles.  
IIIb. Predomin antly affecting oropharyngeal, respiratory muscles, or both. May 
also have lesser or equal involvement of limb, axial muscles, or both.  
Class IV – Severe weakness affecting other than ocular muscles, may also have ocular 
muscle weakness of any severity.  
IVa. Predominantly affecting limb, axial muscles, or both. May also have lesser 
involvement of oropharyngeal muscles.  
IVb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May 
also have lesser or equal involvement of limb, axial muscle s, or both.  
Class V – Defined by intubation, with or without mechanical ventilation, except when 
employed during routine postoperative management.    
 
6.4.10  Study Medication/Intervention Discontinuation Evaluations/ Procedures  
 
Subjects will be monitored through regular physical examinations, vital signs, laboratory tests, 
and incidence and severity of adverse events. Infections will be treated symptomatically. 
Cardiovascular risk factors will be assessed prospectively by recording risk factors (e.g., family 
histo ry, smoking history, and status).   The safety evaluations will be conducted on conventional 
safety variables, such as serious adverse events, laboratory tests, and vital  sign changes. In 
particular, B cell counts, immunoglobulin levels, infusion -related re actions, and thromboses, 
infections will be carefully examined.  
 
Adverse events will be reviewed and recorded at each study visit and infusion visit.  An adverse 
event is any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, 
laboratory or physiologic observations occurring in study participants.  Information on adverse 
effects of medication and on inter -current events will be determined at each visit by direct 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 46 of 77 questioning of the subjects, clinical examination, and laboratory t ests. Tolerability will be 
determined by the ability to complete the study on the assigned experimental medication.   
 
Study Hold Rules (Safety) . 
 
Individual study subjects may be withdrawn from the study medication but  continue  to be followed 
for safety if subjects develop a grade 3 or more suspected toxicity as graded by the National 
Cancer Institute’s ( NCI) Common Terminology Criteria for Adverse Events (CTCAE)  Version 4.0 
or a Serious Adverse Event (SAE)  related to study medi cation  as determined by the Independent 
Medical Monitor (IMM) .  Grade 3 adverse events are s evere or medically significant but n ot 
immediately life -threatening and may cause  hospitalization or prolongation of hospitalization 
indicated .  Descriptions of CTC AE grading criteria are included in the Manual of Operations and 
SAEs are specifically defined in Section 10.4.1.2.  Subjects will be allowed to resume participation 
in the study if their suspected toxicity or adverse event (AE) resolves completely and if the 
judgment of the investigator  and IMM  it is safe for the subject to continue.  
 
 
Please see Section 8 for additional details regarding Criteria For Intervention Discontinuation . 
 
Please also see Package Insert and Investigator Brochure  for additional safety information. 
Additional safety monitoring visits will be at the discretion of the investigator or as directed by the 
IRB and/or other regulatory authorities.  
 
Study Stopping Rules (Safety) . 
 
The study will be permanently stopped  and no further administration of rituximab will be given if 
the investigator, the IRB and/or DSMB and/or any other institutional or regulatory body deems it 
inappropriate for the study to resume due to the following:  
 
A significant number of  enrolled subj ects develop safety concerns that cannot otherwise be 
attributed to MG, infections, disease relapse or pre -existent comorbidities  as deemed by the IMM.   
 
 Please also see SOA  for additional safety monitoring information. Additional safety monitoring 
visits  will be at the discretion of the investigator or as directed by the IRB and/or other regulatory 
authorities.  
 
 
6.4.11  Off-Intervention Evaluations  
 
In the event that  a subject is unable to tolerate study drug infusions resulting in the study 
medication being withdrawn but has completed at least one infusion, and is otherwise able to 
comply with study procedures, the subject will be asked to attend all study visits per  protocol.   
 
If the subject is withdrawn from the study, either for being unable to tolerate the study drug (i.e. 
unable to complete any infusions)  or being unable to comply with the remaining study 
procedures, they will go on reduced follow -up. For more i nformation regarding the reduced 
follow - up, please see Section 8 – Criteria for Intervention Discontinuation.  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 47 of 77 There are two additional off study -intervention  time points (week 72 and 96) to assess durability 
of response as well as monitor B cell count no rmalization.  Subjects will have similar clinic al 
evaluations as during the on -study drug intervention period.  Subjects will be treated per 
medical standard of care. For more details regarding these visits, please refer to the SOA  and 
Section 6.4.5.    
 
6.4.12  Unscheduled Visits  
 
Subjects will be clinically evaluated at an Unscheduled Visit at the discretion of the treating 
physician for an y concern of disease relapse and/or significant worsening of symptoms as well 
concern for adverse event related to study.  A standard physical exam and the MGC score 
assessments will be performed during this visit.  Prednisone diary will also be reviewed.  Blood 
work will also be performed as per SOA  and primary study team recommendations .    
 
The following are recommended to be  performed during Unscheduled Visits:  
• Prednisone diaries will be collected and reviewed  
o Prednisone dose may be evaluated and increased at the Unscheduled Visit per Site 
Investigator judgment in cases of clinical worsening. Prednisone tapering should not 
occur at Unscheduled Visits that occur after Week 8. If the Site Investigator feels 
that i t is clinically necessary to taper at the visit, the study team must be consulted 
and provide approval for doing so.  
• Subjects will undergo a complete physical examination  
• Vital signs will be measured  
• Phlebotomy will be performed. For a complete list of re commended lab tests, please see 
Section 6.3.6.  
• Outcome Assessments: MGC  will be completed .  
• Adverse Events will be reviewed and recorded  
• Concomitant medications will be recorded.  
 
6.4.13  Final On -Study Evaluations  
 
Final on -study visit (week 52) includes: physica l exam, vital signs, blood draws, safety 
assessments and specific myasthenia gravis clinical assessments as described above.   
 
**NOTE** All subjec ts will have the option to return for two additional off -intervention  follow -up 
visits (weeks 7 2 and 96) in order to monitor B cell counts along with MG clinical status. This 
portion of the trial will only include subjects that have not received rituximab or other B cell 
depleting treatments after study completion (i.e. Week 52).  B cell levels typically return t o normal 
levels approximately 12+ months following B cell depletion therapy.    
 
6.4.14  Pregnancy  
 
Pregnancy is an exclusion criterion.  Routine testing as described above at screening visit and 
prior to each rituximab infusion will be performed in all women of c hild-bearing age. Men and 
women of reproductive potential must agree to use an acceptable method of birth control during 
treatment and for twelve months (1 year) after completion of treatment.  
 
If a subject becomes pregnant within the course of the study, site staff will be asked to follow the 
subject by telephone to determine the outcome of the pregnancy.  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 48 of 77  
6.5 SPECIAL INSTRUCTIONS AND DEFINITIONS OF EVALUATIONS  
 
6.5.1  Informed Consent  
 
The Clinical Study Site PI (CSS PI)  and all IRB approved Licensed Physician Sub -Investigators 
personnel will be able to obtain informed consent from the participant.  
 
Written informed consent will be obtained from each participant before any study -specific 
procedures or assessments are performed and after the a ims, methods, anticipated benefits, and 
potential hazards are explained. The participant’s willingness to participate in the study will be 
documented in writing in a consent form, approved by the NeuroNEXT CIRB, which will be signed 
by the participant with  the date of that signature indicated. The investigator will keep the original 
consent forms and copies will be given to the participants. It will also be explained to the 
participants that they are free to refuse entry into the study and free to withdraw from the study at 
any time without prejudice to future treatment. Written and/or oral information about the study in 
a language understandable by the participant will be given to all participants. HIPAA guidelines 
for confidentiality and the principles of medical ethics will be adhered to during the study.  
**NOTE** The above statement applies to the secondary consent form for the Week s 72 and 96 
Visits  as well . Subjects may be consented prior to Week 52 or at Week 72 prior to any study -
related procedures being performed.  If the Week 72 window has passed for any given subject, 
but they are willing to coming for Week 96, they can be consented at Week 96 prior to any 
procedures being performed.  
6.5.2  Protocol Violations  
 
Deviations from the written protocol will be  considered a protocol violation and reported to the 
medical monitor and the safety monitoring board.  
6.5.3  Documentation of Myasthenia Gravis  
 
Autoimmune myasthenia gravis will be defined as a person who has the following:  
 
1. Positive serum acetylcholine recept or (AChR) binding  antibodies * in conjunction with  
2. Positive decremental response on repetitive nerve stimulation at 3 Hz, OR a clinical 
examination consistent with generalized myasthenia gravis.  
  
*Positive acetylcholine receptor binding antibodies as def ined by a certified  commercial 
laborator y.  The following are some common labs.    
• Mayo Medical Laboratories: Muscle AChR Binding Antibody >0.02 nmol/L  
• Quest Diagnostics:  AChR Binding Antibody ≥0.50 nmol/L  
• LabCorp: AChR Binding Antibodies >0.40 nmol/L  
6.5.4  Medical History  
 
A routine medical history will be obtained during the screening phase of the trial. Subjects will be 
asked about adverse events at each subsequent visit.   Medical history will be updated at the 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 49 of 77 optional off-intervention follow -up visits to  record only any autoimmune disease(s) that the subject 
has been diagnosed  with betwe en weeks 52 and 72 and weeks 72 and 96 .  
6.5.5  Treatment History  
 
All prior treatments  from the time of diagnosis (a minimum of one year’s history prior to screening)  
with immune therapies (prednisone, azathioprine, mycophenolate mofetil, monoclonal antibodies, 
etc.) will be obtained from the subject source documents.  Treatment history between weeks 52 
and 72 and weeks 72 and 96 will be documented at the optional off-intervention  follow -up visits . 
MG-related medication, including prednisone dose and/or any changes if applicable will be 
recorded.  
6.5.6  Concomitant Medications/Treatments  
 
All immune therapies and treatments that modulate or suppress the immune system will be 
obtained from source documents. MG -related medication (including prednisone dose and/or any 
changes if applicable) taken between weeks 52 and 72 and weeks 72 and 96 will be 
documented at the optional off -intervention follow -up visits. Any immunosuppressive  therapies 
and steroids taken for other diseases will be recorded as well during these visits.   
 
**Note** Subjects who have received treatment with rituximab, or have been involved with other 
interventions that result in B cell depletion since completion o f the trial (i.e. Week 52) will be 
excluded from the optional off -intervention follow -up visits.  
6.5.7  Immunization during B Cell Depletion  
 
The efficacy and safety of i mmunization during periods of B cell depletion have not been 
adequately studied. Subject’s vaccination record and the need for immunization will be  carefully 
evaluated prior to receiving study drug.  For those who are likely to require immunization in the 
foreseeable future, such as subjects planning to travel to countries where specifi c immunization 
is required or subjects requiring vaccination/booster for their professional activity, any required 
vaccination/booster must be given at least 4  weeks prior to the baseline/randomization visit .  
Review of the subject’s immunization status or  need for the following vaccinations in advance of 
randomization  (as noted previously)  will be completed : tetanus, diphtheria, influenza, 
pneumococcus polysa ccharide, varicella, measles, mumps, rubella (MMR) and hepatitis  B, 
vacci nes. Required immunization s should be determined based on a subject’s age and 
comorbidities and are per best medical practice standard.  
 
The safety and efficacy of immunization with a live or at tenuated live vaccine in B  cell depleted 
subject s are not known.  For this reason, the use of live or attenuated vaccines (e.g.,  measles, 
mumps, rubella, oral polio vaccine, Bacillus Calmette -Guérin [BCG], typhoid, yellow fever, 
vaccinia,  varicella -zoster virus ( VZV) or any  other vaccines not yet licensed but belonging to this 
category) is specifically excluded 28  days prior to screening through the end of the 52 week 
follow -up period or until return of B  cells to within normal limits or baseline.  
 
Vaccines that do not cont ain live organisms (e.g.,  influenza, Pneumovax , tetanus) are not 
prohibited; however, vaccinat ions during B cell depletion may be ineffective.  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 50 of 77 6.5.8  Protocol Amendments and Study Termination  
All revisions and/or amendments to this protocol must be approved in writing by the Sponsor and 
the CIRB. The Investigator will not make any changes to the conduct of the study or the protocol 
without first obtaining written approval from the Sponsor and the CIRB, except where necessary 
to eliminate an apparent immediate ha zard to a study subject.  
The Sponsor and NeuroNEXT Network reserve the right to discontinue the study at a clinical study 
site(s) for safety or administrative reasons at any time. Should the study be terminated  and/or the 
clinical study site closed for any reason, all documentation and study medication pertaining to the 
study must be returned to the Sponsor or its representative.  
 
6.5.9  Clinical Assessments  
 
Subject s will have clinical evaluations at the Baseline Vis it and then every 4 weeks thereafter 
(week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52).  Post -intervention status will be assessed 
by measuring the MGFA  clinical classification grade , MGC, QMG, MG -ADL and MG -QOL scores . 
Most of t hese clinical evaluat ions will also be completed at unscheduled visits  (MGC only) as well 
as at weeks 72 and 96 (all except  QMG ). The dose of prednisone will be recorded by each subject  
daily and collected at each scheduled evaluation.  These will be recorded on the CRFs.   
 
All appropriate MG -specific common data elements as determined by the protocol steering 
committee will be collected and recorded on CRFs.  
 
Adverse effects will be monitored to assess safety and tolerability in this subject  population per 
Genentech and DAIT ’s guidelines.  
6.5.10  Laboratory Evaluations  
 
The Investigator will review, sign and date all lab reports .  The investigator will indicate if out of 
range lab value is Clinically Significant “CS” or Not Clinically Significant “NCS” on the lab report.   
CTCAE version 3.0 will be used for grading events . 
 
Safety labs will be drawn and analyzed  locally up to 1 day  prior to each infusion visit.  All other 
labs will be analyzed centrally and sent to CMSU.  
 
Subject s will be instructed not to take pyridostigmine for at least 12 hours prior to the Baseline  
Visit and each follow -up visit , including the optional Week 72 and Week 96 Visits .   
 
Subjects are asked not to take their usual p rednisone dose on the day of the Baseline Visit, 
Week 24  Visit, Week 52  Visit, as well  as the optional Week 72 and Week 96 Visit s. 
 
• Pregnancy Testing.   All women of childbearing potential will have a serum pregnancy test 
at Screening and urine pregnancy test at Baseline and all Infusion Visits (infusion visit 1, 
2, 3, 4, 5, 6, 7 and 8) .  The serum pregnancy test will be analyzed centrally.  The urine 
pregnancy tests will be locally read.    
 
• Standard Bloods.   All subjects will have standard safety blood work completed at the 
Screening Visit and week 52.  These include: comprehensive metabolic panel, uric acid, 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 51 of 77 LDH and  CBC with platelets and differential .  These labs will be shipped to CMSU to be 
analyzed cent rally.  
 
• HbA1C  will be checked at the Screening and Week 52 Visits. These labs will be shipped 
to CMSU to be analyzed centrally.  
 
• Infusion Labs . Complete metabolic panel, uric acid, LDH  and CBC with differential will be 
analyzed locally up to 1 day prior to each infusion.  Site Investigators will review the lab 
results prior to the infusion.  Site Investigators may hold the rituximab infusion if the lab 
results indicate that the subject is not medically able to tolerate the infusion.   
 
• Serolog y Testing. All subjects  will have hepatitis panel and HIV testing completed at the 
Screening Visit .  These labs will be shipped to CMSU to be analyzed centrally.   Subjects 
will be referred to  pre-test and post -test counseling and provide d with an information 
sheet.  
 
• Specialized Bloods.   All subjects will have specialized blood work completed at the  
Baseline Visit, Week 24, Week 52 , and optional Week 72 and Week 96  Visits.  These 
include: 1. AChR antibody titer (Mayo Medical Laboratory, Rochester, MN). 2. Total  IgG, 
IgA and IgM levels.  3. IgG subclasses (1,  2, 3 and 4).  4. Flow C ytomet ry to assess B 
cell count.  These labs will be shipped to CMSU to be analyzed centrally.    
 
• Biomarker/Mechanistic Blood .  The biomarker or mechanistic studies are focused on 
identifying how treatment modifies the immunopathology of MG. These blood draws will 
be completed at the Baseline Visit, Week 24, Week 52 , and optional Week 72 and Week 
96 Visits. Samples will be kept at room temperature and shipped priority overnight to Dr. 
Kevin O’Connor’s Laboratory at Yale University for processing and immunologic studies.   
Deliveries must arrive within 24 hours of collection.   
  
Shipping Address:   
 
  
 
 
 
   
 
 
Refer to SOA and section 6.3.6 for additional details.   
6.5.11  Pharmacokinetic Studies  
 
Pharmacodynamics will specifically be followed by monitoring B cell depletion and repopulation.   
6.5.12  Subject Adherence Assessments  
 
Daily prednisone dose will be recorded in a diary by each subject and reviewed at each scheduled 
clinic evaluation (every 4 weeks).   Adherence to taking prednisone as well as taking correct dose 
of prednisone will be monitore d.    

Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 52 of 77  
6.5.13  Biomarker/Mechanistic Studies  
 
The biomarker or mechanistic studies are focused on identifying how treatment modifies the 
immunopathology of MG. We will study changes in the antigen specific  components of the MG 
immune system. We have developed/adap ted immunoassays so that we can examine 
autoantibodies, B cells and T cells. The principal mechanistic outcome  will be the decrease in titer 
of circulating AChR autoantibodies within an individual. Other e xploratory mechanism -based 
outcomes  include determi ning how rituximab modifies antigen -specific B cell frequency, the B cell 
repertoire, B cell activating factor (BAFF) levels and whether rituximab modifies antigen -specific 
T cell frequency and phenotype. Measurements will be performed prior to and during B cell 
depletion and through repopulation of the B cell compartment, which will be of particular interest 
in terms of assessing the durability of the treatment.   Blood will be collected for mechanistic 
studies at the Baseline Visit,  Week 24 , Week 52  Visits , as well as the optional Week 72 and Week 
96 Visits . 
 
7 MANAGEMENT OF ADVERSE E VENTS  
 
The most common side effects are infusion -related symptoms, particularly with the first rituximab 
infusion.   These symptoms include flu -like symptoms, fever, chills/rigors , nausea, urticaria, 
headache, bronchospasm, angioedema, and hypotension .  Since hypotension may occur during 
rituximab infusion, consideration should be given to withholding antihypertensive medications 12 
hours prior to and throughout rituximab infusion.   The decision to hold antihypertensive 
medications  will be based on  the discretion of local site investigator.  Angina pectoris or cardiac 
arrhythmias, such as atrial flutter and fibrillation, have occurred in subject s treated with rituximab. 
Therefore, subject s with a history of cardiac disease should be monitored closely. In rare 
instances, severe and fatal infusion -related reactions have occurred.   
 
If a hypersensitivity (non -IgE-mediated) or an infusion reaction develops,  the infusion rate should 
be reduced to half that rate, i.e. from 100 mg/h to 50 mg/h.  Subjects who experience a moderate 
to severe infusion related reaction (fever, chills, or hypotension) should have their infusion 
interrupted immediately and should receive aggressive symptomatic tr eatment  per local 
institutional policy or protocol .  The infusion should not be restarted before all the symptoms have 
disappeared and then the infusion can continue at one -half the previous rate.   If hypersensitivity 
reaction should occur, subject will re ceive 100 mg methylprednisolone IV 30 minutes prior to the 
next infusion.  
 
The infusion should be interrupted for severe reactions, and supportive care measures should be 
instituted as medically indicated (e.g., IV fluids, vasopressors, oxygen, bronchodila tors, 
diphenhydramine, and acetaminophen).  The infusion should not be restarted until all the 
symptoms have disappeared.  
  
Pregnancy:  
Pregnancy itself is not regarded as an AE unless there is a suspicion that the study drug  may 
have interfered with the effectiveness of a contraceptive medication. However, the  outcome of all 
pregnancies that occur during paternal or maternal exposure to study drug (spontaneous 
miscarriage, elective termination, normal birth or congenital abnormality) must be followed up a nd 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 53 of 77 documented even after the subject has been withdrawn from the study. All reports of congenital 
abnormalities/birth defects are SAEs. Spontaneous miscarriages should also be reported and 
handled as SAEs. Elective abortions without complications should no t be handled as AEs. All 
outcomes of pregnancy must be reported to the data safety monitor .   
 
Disease -Related Events (DREs):  
Given that variations in symptoms are an inherent part of the natural history of MG, all recorded 
information regarding MG status will be captured as outcomes data. While disease relapse or 
treatment failure is not considered an AE in our study, the DSMB will monitor the percentage of 
treatment failures in the two groups.  If the treatment failure rate reaches a level of concern, the  
DSMB has the ability to stop the trial at any point.  In the setting of a forced steroid taper, we 
expect to possibly observe an increased frequency of disease relapse, particularly in the placebo 
group.  As the forced steroid taper is guided by the MGC s core, we do not expect for this to be a 
significant concern.  Relapses will be managed by increasing the prednisone dose and possibly 
offering PLEX or IVIg (rescue therapies ) depending on severity.  These are standard of care 
practices.   For the purpose o f this study, variation in MG symptoms will not be considered an AE 
unless the MG relapse requires hospitalization for rescue therapy. If a subject is hospitalized for 
an MG relapse, it will be reported as an SAE.  
 
8 CRITERIA FOR INTERVENTION DISCONTINUATION  
 
See section 6.2. 9 
 
Subjects that are withdrawn from the study or intervention discontinued  due to an SAE  will have 
reduced follow -up. This will include being followed monthly via telephone or in person for a 
minimum of 90 days or until SAE resolution , whichever comes first, after which a Termination Visit 
will be conducted. The Termination Visit will mirror the Week 52 Visit.  
• If the SAE is resolved  within 90 days, the Termination Visit can occur  earlier . 
• If the SAE is not resolved wi thin 90 days, the SAE will be R esolved with Sequelae, and 
the Termination Visit occur.  
 
During the 90 day (or less) SAE follow -up period, no new AEs will be recorded. Existing AEs 
would be followed until resolution, or the Termination Visit, whichever comes first.  
 
Subjects tha t are withdrawn from the study or intervention discontinued due to reasons other than 
an SAE, will complete a Termination Visit only – no follow -up will be required.  
 
9 STATISTICAL CONSIDERATIONS  
 
The NeuroNEXT Data Coordinating Center has developed a statistical analysis plan, in 
collaboration with the PPI, co -PPI, co -investigators and protocol steering committee.  
 
9.1 General Design Issues  
 
9.1.1. Summary of Study Design  
 
A previous study conducted at Yale demonstrated that 82% of subjects who received rituximab 
achieved at least a 75% reduction in their prednisone dose at 52 weeks (95% CI: 48% -98%).  The 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 54 of 77 objective of the proposed study is to determine whether the large ben efit observed in the prior 
Yale study can be refuted, or looks promising enough to justify a future phase III trial.  This 
objective will be accomplished using a futility design, which tests the hypothesis that subjects 
treated with rituximab will achieve at least an absolute 30% increase in the frequency of favorable 
responses .60,61  If “futility” is declared , then  the results would imply that it is not cost effective to 
conduct a  future phase III trial with this agent.  If “futility” is not declared, then the study would  
suggest that there could be a potentially clinically meaningful effect of rituximab which shoul d be 
explored in a larger follow -up study.  
 
The proposed study will involve a randomized, double -blind, placebo -controlled multicenter futility 
study with 50 subjects randomized in a 1:1 manner to receive either rituximab or placebo (25 per 
group).  The primary objective of the study is to test whet her rituximab is a beneficial steroid 
sparing therapeutic for myasthenia gravis subject s.  A predetermined steroid taper schedule will 
be utilized.  At the time of enrollment, each subject  will be expected to be on a stable fixed dose 
of prednisone for at least 28 days (4 weeks).  Subjects assigned to the rituximab group will receive 
a total of two cycles of rituximab separated by six months.  Each cycle is defined as one infusion 
(375 mg/m2) per week for four consecutive weeks.  As such, cycle 1 will be ad ministered at weeks 
0-3 and cycle 2 will be given during weeks 24 -27.  Subjects assigned to the placebo group will 
receive similar cycles of placebo.  
 
MGFA  clinical classification  grade along with quantitative testing (i.e., MG -ADL score, QMG 
score, MG Com posite, MG -QOL) will be assessed every four weeks.  The proposed study 
duration is 52 weeks.  In each subject, the prednisone dose will be gradually reduced based on 
the steroid taper schedule beginning at week 8 (8 weeks after starting cycle 1 of rituxima b).  The 
dose will only be reduced after confirming improvement or minimal stable symptoms based on 
judgment of the examining physician and MG Composite Score.  If symptoms worsen, the 
prednisone dose would immediately be increased until the symptoms impro ved and/or resolved.  
In addition, subject s who worsen can receive PLEX or IVIg if the investigator decides it is 
warranted, and these subject s can remain in the study.  Prednisone taper would again be resumed 
four weeks after the subject s have improved.  The dose of prednisone will be recorded by each 
subject  daily and collected at each evaluation.  
 
The primary endpoint will be a binary indicator of whether a subject achieved at least a 75% 
reduction of prednisone dose from baseline.  The endpoint will be computed by comparing the 
mean daily prednisone dose during the four -week period prior to randomization versus the four 
week period at the end of the study (weeks 49 -52).  Secondary endpoints will include the MGC 
and QMG.  Other exploratory clinical endpoi nts will include MG -ADL, other clinical measures, 
immune markers, and safety evaluations.  There will be a treating investigator who does the dose 
adjustments and a blinded investigator who performs the blinded assessments.  
 
9.1.2. Randomization  
 
Randomiza tion will be performed through an interactive website, and will be stratified based on 
the steroid dose at baseline  [moderate (15 -35 mg/day)  vs. high (>35 mg/day) ] and baseline 
therapy (prednisone only vs. prednisone plus another IST) .  Subjects will be assigned a study ID 
at the time of enrollment.  The study ID includes the identification of the center and a unique 
subject ID.  The DCC will generate a randomization table for each of the strata using a permuted 
block design with random block sizes.  At t he time of randomization, the study coordinator logs 
into the study website and enter s the potential subject’s baseline prednisone dose as well as other 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 55 of 77 eligibility criteria.  The subject will then be randomized to one of the two treatments.  The study 
ID is added to all subsequent CRF’s and on the dispensed study medication.  
9.2 Outcomes  
9.2.1  Primary Outcome (including definition)  
 
The specific primary aim of this study is to determine whether rituximab is a safe a nd shows 
sufficient promise as a steroid sparing therapeutic for MG to warrant further study in a phase III 
efficacy trial.   Refer to Section 9.5 for statistical analysis plan.  
 
Steroid Sparing Effect.  The primary endpoint is the percent of subjects that achieve a ≥ 75% 
reduction in mean daily prednisone in the four weeks prior to week 52 (week 49 -52) along with 
clinical improvement or no significant worsening of symptoms (≤2 point increase  in MG composite 
score)  as compared to the four week period prior to randomization . 
 
Safety . Safety will be assessed by examining the frequency of study -related adverse experiences 
in the two groups.  
9.2.2  Secondary Outcome(s)  
 
Our secondary objective is to evaluate whether there is a trend toward clinical benefit as 
measured by MG -specific clinical ou tcome scales used as endpoints in prior clinical trials.  We 
will determine if rituximab can significantly improve the scores of the following MG -specific clinical 
outcome measures:  (1) Myasthenia Gravis Composite (MGC).   (2) Quantitative Myasthenia 
Gravi s (QMG) .  These studied measures would lay the groundwork toward optimizing the design 
of a subsequent phase III efficacy trial of rituximab in MG.   
 
Myasthenia Gravis Composite (MGC) .  The MGC is a new end-point that has been  developed 
for MG.   Spec ific components of the QMG, MG-ADL, and manual muscle testing scales  are 
combined to obtain  the MGC score.  
 
Quantitative Myasthenia Gravis (QMG) .  The QMG is a validated 13 -item test that objectively 
measures ocular, bulbar, extremity fatigue/strength, and  respiratory function.   A battery of 
quantitative functional tests are completed from which a QMG score  is calculated .  
 
9.2.3  Exploratory Outcomes  
 
9.2.3.1  Clinical Exploratory Outcomes  
 
Determine if rituximab can significantly improve the scores of the following other previously 
validated MG -specific outcome measures: (1) MG -Activities of Daily Living score (MG -ADL).  (2) 
MG-Quality of Life (MG -QOL) score.  
 
Other previously used measures  of steroid -sparing effect will be assessed: (1) Mean daily 
prednisone dose at each scheduled assessment (every 4 weeks). (2) A delayed start of the area 
under the dose -time curve (AUDTC), starting at week 8. (3) Percentage of subject s achieving a ≥ 
50% me an daily prednisone dose reduction with maintenance of minimal or no sympto ms in 4 
weeks prior to week 52.  (4) Body mass index (Screening Visit and weeks 24 and 52).  (5) HbA1C  
(Screening Visit and week 52).   
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 56 of 77  
MG flare rate (failure of therapy) will be as sessed by: (1) Number of rescue treatments (PLEX or 
IVIg) . (2) Number of times prednisone dose needed to be increased. (3) Frequency of a ≥ 3 -point 
increase in the MGC score.  
 
The primary focus of the two observational off study -intervention  time points (weeks 72 and 96) 
will be to assess B cell recovery/repopulation as a safety measure .  Specifically, we will examine: 
(1) Percentage of subjects achieving normal B cell counts at week 72 and 96.  ( 2) Percentage of 
achieving baseline B cell counts at week 72 and 96. (3) Percent B cell recovery to normal or 
baseline levels.  In addition, the long -term durability of response will also be assessed.  
Specifically, we will examine : (1) P ercentage of subje cts achieving a sustained ≥ 75% mean daily 
prednisone dose reduction . (2) Percentage of subject s achieving a ≥ 50% mean daily prednisone 
dose reduction . (3) Prednisone AUDTC (if applicable). (4) Clinical status as measured by MGFA 
Class, MGC, MG -QOL and MG -ADL scores. (5) Number of rescue treatments (PLEX or IVIg) . 
9.2.3.2  Biomarker/Mechanistic Exploratory Outcomes  
 
The biomarker or mechanistic studies are focused on identifying how treatment modifies the 
immunopathology of MG. We will study changes in the antigen specific  components of the MG 
immune system. We have developed/adapted immunoassays so that we can examine 
autoantibodies, B cells and T cells. The principal mechanistic outcome  will be the decrease in titer 
of circulating AChR  autoantibodies within an individual. Other e xploratory mechanism -based 
outcomes  include determining how rituximab modifies antigen -specific B cell frequency, the B cell 
repertoire, B cell activating factor (BAFF) levels and whether rituximab modifies anti gen-specific 
T cell frequency and phenotype. Measurements will be performed prior to and during B cell 
depletion and through repopulation of the B cell compartment, which will be of particular interest 
in terms of assessing the durability of the treatment.   Blood will be collected for mechanistic 
studies at the Baseline Visit,  Week 24 . Week 52  Visits , as well as the optional  Week 72 and Week 
96 Visits . 
9.3 Sample Size and Accrual  
Below, we introduce some key notation that we use to describe the analysis plan fo r the 
proposed trial:  
• Let pP represent the true (unknown) percentage of subjects treated with placebo who will 
achieve success on the primary endpoint  
• Let pR represent the true (unknown) percentage of subjects treated with rituximab who 
will achieve success on the primary endpoint  
Based on a prior study completed by Sanders and coworkers in 2008 on MMF in AChR+ MG, 
38.6% of placebo treated case achieved a trea tment response .38 The placebo start point was 34.1 
mg prednisone ; hence, 38.6% of placebo recipients had a reduction of prednisone dose by at 
least 78%.  Also the MMF  start point was 30.7 mg prednisone ; therefore , 44.3% of MMF  recip ients 
had a reduction of prednisone dose by at least 76%.  Based on this information, we assume that 
40% of placebo recipients will achieve a 75% or greater prednisone dose reduction ( pP = 0.40).  
The design of this trial was somewhat restricted due to the fact that the company that produces 
rituximab has only agreed to provide 25 doses to the investigators.  As a consequence, this 
study requires more of a sample size justification (for the sample size fixed by external factors) 
as opposed to a standard samp le size calculation that determines the required sample size for a 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 57 of 77 fixed target power.  Using the notation above, the one -sided futility hypothesis that the treatment 
achieved the desired clinically meaningful level of interest may be stated as:  
𝐻0,𝐹:𝑝𝑅−𝑝𝑃≥0.30     𝑣𝑠.     𝐻𝐴,𝐹:𝑝𝑅−𝑝𝑃<0.30. 
Therefore, rejecting the null hypothesis suggests ‘futility’ in the sense that it appears unlikely 
that conducting a future phase III clinical trial would lead to a significant effect with a magnitude 
at least as large as the specified clinically meaningful effect of interest.  If we don’t reject the null 
hypothesis, this would provide one of the “go” conditions for conducting a future phase III study.    
The table below shows the power computed across a ra nge of assumed values for the true 
response rate in the rituximab subjects.  The calculations assume a type I error rate of 10%, pP 
= 0.40, and a conservative assumption of up to 20% missing data.  The table below 
demonstrates the benefits of using the fut ility design.  When the true success rate for rituximab 
is near or below the true success rate for placebo, the study will declare “futility” with high 
probability.  Likewise, when the true success rate for rituximab is well above the true success 
rate for  placebo, the study has a very low chance of incorrectly declaring “futility”.  Given the 
sample size limitations mentioned above, we feel that this provides a reasonable chance of 
having a successful study – where “success” is defined as answering the mai n question of 
interest regarding whether there is clear evidence to rule out an effect of rituximab in this 
population, or to provide enough evidence to justify a larger trial in the future.   
 
Rituximab  
Rate ( pR)  
30%  
35%  
40%  
45%  
50%  
55%  
60%  
65%  
70%  
75%  
80%  
85%  
90% 
Pr(Futility)  92% 84% 74% 63% 50% 37% 25% 16% 10% 4% 2% 1% <1% 
 
9.4 Data Monitoring  
 
All aspects of the study will be monitored by qualified individuals designated by the sponsor.  
Monitoring will be conducted according to Good Clinical Practice and applicable government 
regulations.  The investigator agrees to allow monitors access to the clinical supplies, dispensing 
and storage areas, and to the clinical files of the study subjects, and, if requested, agrees to assist 
the monitors.  
 
Safety monitoring will include careful assessment and appropriate reporting of adverse events.  
Medical monitoring will include contemporaneous  assessment of serious adverse events.  
 
The monitoring of subject safety and data quality will follow the NINDS Gui delines for Data and 
Safety Monitoring in Clinical Trials.  A Data and Safety Monitoring Board (DSMB) appointed by 
the NIH/NINDS will meet at six -month intervals (or as determined by the NINDS) to review partially 
unblinded study data provided by the study  statistician.  This committee will monitor rates of 
adverse events and endpoints in the trial and will monitor the performance of the trial. The 
frequency and format of DSMB meetings, reports, and guidelines for interim analysis will be 
agreed upon prior to study subject enrollment.  
 
The Protocol PI will appoint an Independent Medical Monitor (IMM) to review all adverse events, 
in a blinded fashion, on a periodic basis. In addition , the IMM will review all events that meet the 
regulatory definition of a Se rious Adverse Event, upon receipt of notification via the Electronic 
Data Capture (EDC) system.    
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 58 of 77 An adverse event (AE) is any unfavorable and unintended sign (including a clinically significant 
abnormal laboratory finding, for example), symptom, or disea se temporally associated with a 
study, use of a drug product or device whether or not considered related to the drug product or 
device.  FDA, Office of Human Research Protection (OHRP), and NeuroNEXT CIRB requirements 
for reporting AEs will be followed. Subjects will be monitored for AEs from the time they sign 
consent until the Week 52 Visit. If a new  AE is discovered at the Week 52  Visit, it will be  followed 
until resolution or for a minimum  of 30 days, whichever comes first.  The IMM/DSMB will review 
cumulative AEs ; the frequency of this review will be determined by the IMM/DSMB in conjunction 
with the Protocol PI.  
All SAEs must be followe d until resolution, or until the Week 52 Visit , whichever comes first.  If 
the SAE is still ongoing at Week 52, it will be Resolved with Sequelae.   
• SAEs that are discovered less the 90 days prior to the Week 52 Visit will be followed 
until resolution or for  a minimum of 90 days, whichever comes first , even if it is past the 
Week 52 Visit . A repeat Termination Visit does not need to occur.  
• If a new SAE is discovered at the Week 52 Visit, it must be followed until resolution, or for a 
minimum of 90 days, which ever comes first.  
• For SAEs that result in study treatment discontinuation and a limited follow -up period , please 
refer to Section 8  – Criteria for Intervention Discontinuation .  
 
At the Week 72 and 96 Visits, only those adverse events, serious and non -serious, that in the 
opinion of the Investigator are deemed related  to study procedures will be reported, given that 
the subject has consented to the optional off -intervention follow -up visits. Additionally , any MG 
relapses requiring rescue therapy that have o ccurred since the last visit will also be recorded.  
 
Each Clinical Study Site Investigator and research team (co -Investigators, research nurse, clinical trial 
coordinator) are responsible for identifying and reporting AEs and determining the relationship of the 
event to the study drug/study procedures.  Aggregate reports blinded by treatment group, detailed by 
severity, attribution (expected or unexpected), and relationship to  the study drug/study procedures, 
will be available from the DCC for review by th e IMM. A separate report detailing protocol 
compliance will also be available monthly from the DCC for review by the Protocol PI , who will 
provide feedback to individual sites as needed. The Protocol Steering Committee (PSC) will 
advise the Protocol PI as to whether the protocol or informed consent document require s 
revision based on these reports.  
 
9.5 Statistical Analysi s Plan  
 
9.5.1. Primary Hypotheses  
Primary Futility Hypothesis: Subject s treated with rituximab will have at least a 30% 
absolute increase in  the frequency of achieving at least a 75% reduction in mean daily 
prednisone dose  with maintenance of minimal or no symptoms . 
The primary futility hypothesis being tested in this trial is that subject s treated with rituximab will 
achieve at least an absol ute 30% increase in the frequency of favorable responses.   Assuming a 
placebo response rate of 40% (as in the original sample size calculations), this corresponds to an 
odds ratio of 3.5.  Therefore, the primary futility hypothesis will be assessed using a  logistic 
regression model, adjusted for the two stratification variables, to estimate the log -odds of primary 
endpoint success in each group.  The logistic regression model used for these purposes is stated 
here:  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 59 of 77 𝑙𝑜𝑔𝑖𝑡 (𝑌𝑖)= 𝛽0+ 𝛽1𝑋𝑑𝑜𝑠𝑒 + 𝛽2𝑋𝐼𝑆𝑇,𝑖+ 𝛽3𝑋𝑅𝑀𝐵 ,𝑖 
where  
• Yi represents the binary variable indicating whether or not the ith subject met the primary 
outcome requirement of a 75% or greater reduction in prednisone dose   
• Xdose ,i is an indicator variable  for prednisone dose at basel ine (=0 if moderate , =1 if high)  
• XIST,i is an indicator variable for whether the subject was receiving prednisone plus IST at 
baseline (=0 if prednisone alone , =1 if prednisone plus IST )  
• XRMB,i is an indicator variable for whether the ith subject was randomized to the Rituximab  
group  
Correspondingly, the primary futility hypothesis of interest can be assessed by performing the 
following hypothesis test:  
𝐻0,𝐹:log (𝛽3)≥3.5     𝑣𝑠.     𝐻𝐴,𝐹:log (𝛽3)<3.5. 
Therefore, rejecting the null hypothesis suggests ‘futility’ in the sense that it appears unlikely that 
conducting a future phase III clinical trial would lead to a significant effect with a magnitude at 
least as large  as the specified clinically meaningful effect of interest.  If we don’t reject the null 
hypothesis, this would provide  justification for proceeding to examine the superiority hypothesis .   
Due to randomization, it is unlikely that important covariates wil l be imbalanced in this study.  
However, given the small sample size, this cannot be dismissed.  We will assess for important 
baseline imbalances, and if any imbalances exist, we will adjust for these additional covariates in 
the logistic regression model.  
 
Primary Safety Hypothesis: There will be no increase in adverse experiences for the 
rituximab -treated vs. placebo subject s. 
The second primary hypothesis will involve a comparison of the safety profiles of rituximab vs. 
placebo.  As described elsewhere, general assessments of safety will occur throughout the trial 
in conjunction with the medical safety monitor.  This specific hypothesis will be assessed in two 
ways.  First, the percentage of subjects who experience a study -related AE, overall and by body 
system, will be compared across the two groups using standard chi -square tests.  Then, the rates 
of study -related AE’s across the two groups will be compared using a Poisson regression model.  
 
9.5.2. Secondary Hypotheses  
 
Secondary Hypothesis #1: Rituximab -treated subjects will have clinically significant 
improvement in their Myasthenia Gravis Composite (MGC) scores at the end of the 52 week 
treatment period.  
The first secondary hypothesis assesses the change in Myasthenia Gravis Composite ( MGC ) 
scores  at the end  of the 52 week study period.  The outcome will be defined as the change from 
baseline to week 52 in the MGC.  This hypothesis will be assessed using a linear regression 
model, adjusted for baseline MGC score.  For example, the following model w ill be fit to these 
data:  
 
𝑌𝑖= 𝛽0+ 𝛽1𝑋𝑑𝑜𝑠𝑒 + 𝛽2𝑋𝐼𝑆𝑇,𝑖+ 𝛽3𝑋𝑀𝐺𝐶 ,𝑖+ 𝛽3𝑋𝑅𝑀𝐵 ,𝑖 
where  
• Yi represents the change from baseline in the MGC score for the ith subject  
• Xdose ,i is an indicator variable  for prednisone dose at baseline ( =0 if moderate , =1 if high)  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 60 of 77 • XIST,i is an indicator variable for whether the subject was receiving prednisone plus IST at 
baseline (=0 if prednisone alone , =1 if prednisone plus IST )  
• XMGC ,i is the baseline MGC score for the ith subject   
• XRMB,i is an indicator variable for whether the ith subject was randomized to the Rituximab  
group  
Correspondingly, the secondary hypothesis of interest can be assessed by performing a test of:  
H0: β4 = 0 vs. H A: β4 ≠ 0. 
As above, should important treatment imbalances occur across treatment groups with respect to 
covariates of interest, the model will be adjusted to control for these additional covariates.  
 
Secondary Hypothesis #2: Rituximab -treated subjects will have clinically significant 
improvement in the ir Quantitative Myasthenia Gravis (QMG) scores at the end of the 52 
week treatment period.  
 
The second secondary hypothesis assesses the change in Quantitative Myasthenia Gravis 
(QMG ) scores over the course of the 52 week  study period.  Because the only difference between 
this and the first secondary hypothesis is the choice of outcome, the analysis will proceed in the 
same manner described above for the first secondary hypothesis.  
 
Secondary Hypothesis #3: Rituximab subje cts will have complete B -cell recovery by the 
end of the 96 week assessment period.  
 
The third secondary hypothesis will assess the rate of B -cell recovery among subjects treated 
with rituximab during the study.   The rate of B -cell recovery will be assesse d by quantifying the 
percentage of subjects who: 1) return to their individual baseline level of B -cells, and 2) return to 
either the individual baseline level of B -cells or the lower limit of ‘normal’ based on the central 
lab (whichever is lower).   Point estimates, and 95% confidence intervals, will be computed for 
the rate of B -cell recovery at both 72 & 96 weeks.   If rates are high, as expected, exact methods 
for the computation of confidence intervals will be utilized.   We expect the upper limit of the 
confidence intervals to include the value 100% - which would support a high rate of B -cell 
recovery in this population.   Any subject who receives open -label rituximab treatment after 
Week 52 would be excluded from this analysis as well as from the extended  follow -up study.  
 
9.5.3. Exploratory Analyses  
  
Additional exploratory clinical outcomes  will be investigated to monitor effectiveness as well as 
evaluate other endpoints that would be useful in optimizing future MG trial designs as well as a 
Phase III rituximab trial.  We will assess whether rituximab can improve the scores on the MG -
Activities of Daily Living (MG -ADL) and MG -Quality of Life (MG -QOL) scales.  We will also 
assess other measures of steroid -sparing effect: 1. Mean daily prednisone dose in the 4 weeks 
prior to week 52. 2. Mean daily prednisone dose in the 8 weeks prior to week 52. 3. Percentage 
of subject s achieving a ≥ 50% mean daily prednisone dose reduction with main tenance of 
minimal or no symptom s in 4 weeks prior to week 52. 4. Mean da ily prednisone dose at each 
scheduled assessment (every 4 weeks). 5. A delayed start of the area under the dose -time 
curve (AUDTC), started at week 8.  Failure of therapy (or MG flare rate) will be assessed by 
examining the number of rescue treatments  (PLE X or IVIg) , number of times prednisone dose 
needed to be increased, and the frequency of a ≥ 3 point increase in the MGC score. In addition 
we will review the following predictable steroid related effects between the two groups: 1) 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 61 of 77 HbA1C  (screening and week 52); 2) BMI (screening, week 24 and week 52).  A formal statistical 
analysis plan for these outcomes will be prepared and approved prior to f inal data lock by the 
protocol steering committee.  Finally, we assess B cell recovery/repopul ation as a safety 
measure at the optional observational off study -intervention  time points (weeks 72 and 96)  
along with MG clinical status  during off study -intervention . A formal statistical analysis plan for 
these outcomes will be prepared and approved pr ior to f inal data lock by the protocol steering  
committee . Refer to Section 9.2.3.1.   
 
9.5.4. Impact of Missing Data  
 
The primary analysis will follow the intent -to-treat (ITT) paradigm.  All enrolled subjects must be 
included in the primary ITT analysis, and will be analyzed in the treatment group to which they 
were initially randomized.  As such, it will be critically i mportant to minimize the occurrence of 
missing data.  Obviously, the optimal strategy for dealing with missing data is to make every effort 
to obtain complete data during the conduct of the study.  Our team of data managers and protocol 
coordinators will w ork diligently and use a variety of methods in order to minimize the percentage 
of missing data in this trial.  Nevertheless, there is likely to be a small percentage of missing data.  
For the primary analysis, we will take a conservative approach.  If the  mean prednisone dose is 
not known during weeks 49 -52, then that subject will be considered to not have achieved a 75% 
dose reduction (i.e., they will be counted as a failure).  In order to further assess the potential 
dependence of the results of the prim ary analysis o f these missing values, a series of sensitivity 
analyses will be conducted, including:  
• A Multiple Imputation Approach: This multiple imputation approach will be implemented 
using a model based on the prednisone dose at baseline and all observ ed time points for 
subjects throughout the study.  We will use five separate im plementations of this 
approach, and will average the parameters across the five imputations for the final 
analysis.  
• Using Only Observed Data (No Imputation)  
• Using a Last Observa tion Carried Forward Approach  
• Worst -case scenario: Assume all missing subjects in the rituximab group did not achieve 
a dose reduction and all missing subjects in the placebo group did achieve a dose 
reduction  
• Best-case scenario: Assume all missing subject s in the rituximab group did achieve a dose 
reduction and all missing subjects in the placebo group did not achieve a dose reduction.  
 
 
10 DATA COLLECTION, SITE MONITORING, AND ADVERSE EXPERIENCE REPORTING  
10.1 Data Management  
 
Site personnel will collect, transcribe, correct, and transmit the data onto source documents, 
CRFs, and other forms used to report, track and record clinical research data.  The DCC will 
monitor clinical sites to ensure compliance with data management requirements and Good 
Clinical P ractices. The DCC is responsible for developing, testing, and managing clinical data 
management activities, as required, at the study sites, the CCC, and at the DCC.  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 62 of 77 The general NINDS Common Data Elements (CDE) will be used to construct data collection 
forms. All study data will be collected via systems created in collaboration with the DCC and will 
comply with all applicable guidelines regarding subject  confidentiality and data integrity.  
10.1.1  Registration  
 
Registration of participants on this protocol will em ploy an interactive data system in which the 
clinical study site will attest to the participant’s eligibility as per protocol criteria and obtain 
appropriate informed consent. NeuroNEXT CIRB approval for the protocol must be on file at the 
DCC before accru al can occur from the clinical study site.  
 
The DCC will use a system of coded identifiers to protect participant confidentiality.   When the 
participant is registered to participate in the study using the DCC -provided web -based registration, 
the system wil l assign a participant ID number.  The unique ID code will include a protocol ID, a 
site ID, and a unique participant ID.  To confirm the correct participant ID, the data entry system 
will require a second entry of the unique participant ID and compare for consistency.  In this 
fashion, no personal identifiers would be accessible to the DCC and the data will be collected on 
the correctly identified subject.  
10.1.2  Data Entry  
 
Data entry will occur at the enrolling clinical study sites. Data quality assurance and a nalyses will 
be performed by the DCC.  The DCC, located at the University of Iowa, will coordinate all data 
and statistical services for the study, as well as on -site monitoring for all participating clinical study 
sites.  
 
Data collection for this study wi ll be accomplished with online electronic case report forms.   Using 
encrypted communication links, online forms will be developed that contain the requisite data 
fields.    
 
10.2 Role of Data Management  
 
Data Management (DM) is the development, execution and supervision of plans, policies, 
programs, and practices that control, protect, deliver, and enhance the value of data and 
information assets.  
 
All data will be managed in compliance with NeuroNEXT policies, and applicable Sponsor and 
regulatory requirement s. The DCC will instruct site personnel to collect, transcribe, correct, and 
transmit the data onto source documents, CRFs, and other forms used to report, track and record 
clinical research data.  The DCC will monitor clinical sites to ensure compliance w ith data 
management requirements and Good Clinical Practices. The DCC is responsible for developing, 
testing, and managing clinical data management activities, as required, at the clinical study sites 
(CSS), the CCC, and at the DCC.  
 
The DCC is responsible  for all aspects of clinical data management, and for properly instructing 
key study personnel (including the CCC, the CSS, and DCC staff) on how to collect, transcribe, 
correct and transmit the data onto CRFs or other data collection forms and logs.  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 63 of 77 The DCC is responsible for establishing procedures to ensure that clinical data management 
activities occur as required at the CCC, the CSS, and at the DCC.  
10.3 Quality Assurance  
By signing this protocol, the Sponsor and Investigator agree to be responsible for im plementing 
and maintaining quality control and quality assurance systems with written standard operating 
procedures (SOPs) to ensure that studies are conducted and data are generated, documented, 
and reported in compliance with the protocol, accepted stand ards of GCP, and all applicable 
federal, state, and local laws, rules and regulations relating to the conduct of the clinical study.  
10.3.1  Development of Monitoring Plan  
Onsite monitoring visits will be conducted by DCC monitors according to a pre -defined Monitoring 
Plan.  The monitoring plan will detail the frequency of on -site visits, the study data to be monitored, 
the review of any regulatory files, drug and supplies accountability (if applicable), documentation 
of the on -site visit, and the resolution process for data errors that are discovered during the visits.   
All participating clinical study sites will be monitored at least once after a study initiation visit and 
all sites will have a close -out visit for each protocol.  One on -site monitoring visi t is anticipated for 
each clinical study site per year.  All subjects will be monitored for inclusion and exclusion criteria, 
informed consent procedures, and adverse events.  A certain percentage of data is also 
monitored/ source data verified against the  data entered into the study database.  The monitoring 
plan will include flexibility to revise the frequency of visits or data monitored depending on clinical 
study site or study related issues.  
 
 
10.3.2  Site Monitoring Visits  
 
On-site monitoring visits will be c onducted by DCC monitors according to a pre -defined monitoring 
plan for each protocol.  The goal of on -site monitoring is to analyze (review) the data as it is 
collected, to check the validity and integrity of the data, to verify source documentation, to e nsure 
protection of human subjects, and to ensure protocol compliance with federal regulations.  During 
the monitoring visit, the monitor assesses the overall status of the study, staff, and facilities to 
determine whether the study is being conducted per protocol and in compliance with regulatory 
requirements.  The monitor also conducts a CRF review that includes checks of all adverse event 
documentation, verifies the presence of all critical correspondence and records related to 
investigational products a nd clinical supplies (if applicable), and determines if protocol violations 
have occurred and are documented properly.  After the monitoring visit, the monitor documents 
the results of the monitoring visit and completes a post -visit monitoring letter that conveys any 
issues discovered during the visit and the need for data corrections, if appropriate.  Drug and 
supplies accountability may also be monitored during the site visit.  The DCC will work closely 
with the CCC to monitor and document drug distributi on from the manufacturers to the clinical 
study sites (CSS).  Each CSS will be provided with a drug accountability log which will be reviewed 
by the DCC monitors and recon ciled with distribution logs. At the study closeout visit, the monitors 
confirm that appropriate data have been reviewed, source documentation has been verified, and 
all required documents are present in the Study Regulatory File.  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 64 of 77 10.3.3  Laboratory Data Flow  
Specialized bloods . The DCC will provide laboratories with online forms and/or electronic  data 
exchange mechanisms - depending on their capabilities and needs - to enter, update and obtain 
relevant data.  When biologic sample has been obtained, the clinical study site study coordinator 
will send the sample (participant ID, site ID, and protocol  ID numbers will be used) to the University 
of Rochester central laboratory ). Results will be sent via a secure system to University of 
Rochester laboratory with no individual -identifying information on the report. The laboratory will 
electronically commun icate the test results to the respective clinical study sites in a secure 
manner.   The laboratory will also transfer test results electronically to the DCC.  
Safety Monitoring Labs . The safety monitoring labs will be performed at specific visits  as part of 
routine care.  The DCC will provide online forms and/or electronic data exchange mechanisms - 
depending on their capabilities and needs - to enter, update and obtain the results from these 
tests.   Results that meet criteria for adverse experience reporting , including study drug 
discontinuation will be reported in accordance with guidelines noted below.    
 
Biomarker/Mechanistic Blood . When biologic sample has been obtained, the clinical study site 
study coordinator will send the sample (participant ID, site ID, and protocol ID numbers will be 
used) to Dr. Kevin O’Connor’s Laboratory at Yale University.  Samples will be kept at room 
temperature and shipped priority overnight for processing and immunologic studies.   Deliveries 
must arrive within 24 hours of collection.  
10.4 Adverse E vent Reporting  
 
The adverse event (AE) definitions and reporting procedures provided in this protocol comply with 
all applicabl e United States FDA regulations and International Conference on Harmonization 
(ICH) guidelines.  The Site Investigator will carefully monitor each subject throughout the study 
for possible adverse events.  All AEs will be documented on CRFs designed specif ically for this 
purpose.  It is important to report all AEs, especially those that result in permanent discontinuation 
of the investigational product being studied, whether serious or non -serious.  
 
All SAEs must be followed until resolution, or until the Week 52 Visit, whichever comes first. If 
the SAE is still ongoing at Week 52, it will be Resolved with Sequelae.  
• SAEs that are discovered less the 90 days prior to the Week 52 Visit will be followed  
until resolution or for a minimum of 90 days, whichever comes first , even if it is past the 
Week 52 Visit . A repeat Termination Visit does not need to occur.  
• If a new SAE is discovered at the Week 52 Visit, it must be followed until resolution, or 
for a m inimum of 90 days, whichever comes first.  
• For SAEs that result in study treatment discontinuation and a limited follow -up period , 
please refer to Section 8  – Criteria for Intervention Discontinuation .  
 
At the Week 72 and 96 Visits, only those adverse even ts, serious and non -serious, that in the 
opinion of the Investigator are deemed related  to study procedures will be reported, given that 
the subject has consented to the optional off -intervention follow -up visits. Additionally any MG 
relapses requiring res cue therapy that have occurred since the last visit will also be recorded.  
Each clinical study site’s Principal Investigator and research team are responsible for identifying 
adverse events and reporting them through the DCC Online Adverse Event Reporting  System.  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 65 of 77 Investigators are also responsible for complying with NeuroNEXT CIRB’s reporting requirements 
for all safety reports.  Copies of each report and documentation of IRB notification and receipt will 
be kept in the investigator’s study file.  
On-line Adverse Event Reporting System  
 
Upon entry of a serious adverse event by a site investigator, the DCC Online Adverse Event 
Reporting System will immediately notify the Independent Medical Monitor (IMM).   
 
• Within 24 hours  (of learning of the event), investigators must report any Serious Adverse Event 
(SAE) . Investigators must report all other AEs within 5 working days/7 calendar days  (of 
learning of the event).  
 
Serious adverse events : The site investigator determines caus ality (definitely not related, probably 
not related, possibly related, probably related, definitely related) of the adverse event. The IMM 
will review the SAE report.  The IMM may request further information if necessary.  The Online 
Adverse Event Reportin g System maintains audit trails and stores data (and data updated) and 
communication related to any adverse event in the study.  The IMM may determine that the 
Serious Adverse Event requires expedited reporting to the FDA.  The DCC will prepare a 
Medwatch safety report for submission to the FDA  and to Genentech .  If warranted, the IMM will 
notify the DSMB chair.  The DSMB may suggest changes to the protocol or consent form to the 
Study Chair as a consequence of adverse events.  
 
Non-serious adverse events : Non -serious adverse events that are reported to or observed by the 
investigator or a member of his or her research team will be submitted to the DCC in a timely 
fashion (within 5 working days /7 calendar days ). The events will be presented in tabular form  and 
given to the IMM on a quarterly basis or as requested. Local site investigators are also required 
to fulfill all reporting requirements of their local institutions.  
 
For the purposes of this study, before randomization , only those adverse events, seri ous and non -
serious, that in the opinion of the Investigator are deemed related  to study procedures will be 
reported.  After randomization, all adverse events will be reported.  
 
The DCC will prepare aggregate reports of all adverse events (serious/not seri ous, 
expected/unexpected and relationship to study drug) for the IMM  and the  DSMB on a quarterly 
basis or as requested. In addition, all adverse events will be coded using the MedDRA system. A 
separate report detailing protocol compliance will also be avai lable from the DCC for DSMB and /or 
site review monthly or as requested. The research team will then evaluate whether the protocol 
or informed consent document requires revision based on the reports.  
 
IND Annual Reports  
In accordance with the regulation 21  CFR § 312.32, the Sponsor -Investigator would be required 
within 60 days of the anniversary date that the IND went into effect to submit a brief report of the 
progress of the investigation.   This study has Exempt IND status and as such there are no 
require d annual IND reports to the FDA.   The section below details additional reporting 
requirements.   
 
Safety Reporting Requirements for IND Exempt Studies  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 66 of 77 For Investigator Sponsored IND Exempt Studies, there are some reporting requirements for the 
FDA in accordance with the guidance set forth in 21 CFR 314.80.  
 
Postmarketing 15 -Day “Alert Report”:  
 
The Sponsor -Investigator is required to notify the FDA of any fatal or life -threatening adverse 
event that is unexpected and assessed by the investigator to be possibly related to the use of 
Rituximab. An unexpected adverse event is one that is not already described in the Investigator 
Brochure.   
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
   
 
   
      
 
      
 
 
10.4.1  Definitions of Adverse Events, Suspected Adverse Drug Reactions & Serious 
Adverse Events  
10.4.1.1  Adve rse Event and Suspected Adverse Drug Reactions  
 
An AE is any  untoward medical occurrence associated with the use of a drug in humans, whether 
or not considered drug related .  
 
Adverse drug reactions (ADR) are all noxious and unintended responses to a medicinal product 
related to any dose.  The phrase “responses to a medicinal product” means that a causal 
relationship between a medicinal product and an adverse event is at least a  reasonable possibility, 
i.e., the relationship cannot be ruled out.  Therefore, a subset of AEs can be classified as 
suspected ADRs, if there is a causal relationship to the medicinal product.  
 
Examples of adverse events include: new conditions, worsening  of pre -existing conditions, 
clinically significant abnormal physical examination signs (i.e. skin rash, peripheral edema, etc), 

Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 67 of 77 or clinically significant abnormal test results (i.e. lab values or vital signs), with the exception of 
outcome measure results , which are not being recorded as adverse events in this trial (they are 
being collected, but analyzed separately). Stable chronic conditions (i.e., diabetes, arthritis) that 
are present prior to the start of the study and do not worsen during the trial ar e NOT considered 
adverse events. Chronic conditions that occur more frequently (for intermittent conditions) or with 
greater severity, would be considered as worsened and therefore would be recorded as adverse 
events.  
 
Adverse events are generally detected  in two ways:  
  
Clinical  symptoms reported by the subject or signs detected on examination.  
Ancillary Tests  abnormalities of vital signs, laboratory tests, and other diagnostic procedures 
(other than the outcome measures : the results of which are not being captured as AEs).  
 
If discernible at the time of completing the AE log, a specific disease or syndrome rather than 
individual associated signs and symptoms should be identified by the Site Investigator and 
recorded on the AE log.  However, if an obse rved or reported sign, symptom, or clinically 
significant laboratory anomaly is not considered by the Site Investigator to be a component of a 
specific disease or syndrome, then it should be recorded as a separate AE on the AE log.  
Clinically significant laboratory abnormalities, such as those that require intervention, are those 
that are identified as such by the Site Investigator.  
 
An unexpected adverse event is any adverse event, the specificity or severity of which is not 
consistent with the current In vestigators Brochure  or package insert or described in the protocol .  
An unexpected, suspected adverse drug reaction is any unexpected adverse event that, in the 
opinion of the Site Investigator or Sponsor, there is a reasonable possibility that the invest igational 
product caused the event.  
10.4.1.2  Serious Adverse Events  
 
A SAE is defined as an adverse event that meets any of the following criteria:  
 
1. Results in death.  
2. Is life threatening: that is, poses an immediate risk of death as the event occurred.  
a. This serious  criterion applies if the study subject, in the view of the Site Investigator or 
Sponsor, is at immediate risk of death from the AE as it occurs .  It does not apply if an 
AE hypothetically might have caused death if it were more severe.  
3. Requires inpatient hospitalization or prolongation of existing hospitalization.  
a. Hospitalization for an elective procedure (including elective PEG tube/g -tube/feeding 
tube placement) or a routinely scheduled treatment is not an SAE by this criterion 
because an elective or sch eduled “procedure” or a “treatment” is not an untoward 
medical occurrence.  
4. Results in persistent or significant disability or incapacity.  
a. This serious criterion applies if the “disability” caused by the reported AE results in a 
substantial disruption of th e subject’s ability to carry out normal life functions.  
5. Results in congenital anomaly or birth defect in the offspring of the subject (whether the 
subject is male or female).   
6. Necessitates medical or surgical intervention to preclude permanent impairment of a body 
function or permanent damage to a body structure.  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 68 of 77 7. Important medical events that may not result in death, are not life -threatening, or do not 
require hospitalization may also be considered SAEs when, based upon appropriate medical 
judgment, may je opardize the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition.  Examples of such medical events include 
blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the  
development of drug dependency or drug abuse.  
 
An inpatient hospital admission in the absence of a precipitating, treatment -emergent, clinical 
adverse event may meet criteria for "seriousness" but is not an adverse  experience, and will 
therefore, not be c onsidered an SAE.  An example of this would include a social admission 
(subject admitted for other reasons than medical, e.g., lives far from the hospital, has no place to 
sleep).  
 
A serious, suspected adverse drug reaction is an SAE that, in the opinion o f the Site Investigator 
or Sponsor, suggests  a reasonable possibility that the investigational product caused the event.  
 
The Site Investigator is responsible for classifying adverse events as serious or non -serious.  
10.4.1.3  Pregnancy  
 
If a female subject becomes pregnant while receiving investigational therapy or within 90 days 
after the last dose of study drug, a report should be completed and expeditiously submitted to 
the Genentech, Inc. Follow -up to obtain the outcome of the pregnancy should also occur. 
Aborti on, whether accidental, therapeutic, or spontaneous, should always be classified as 
serious, and expeditiously reported as an SAE. Similarly, any congenital anomaly/birth defect in 
a child born to a female subject exposed to the {study drug} should be repo rted as an SAE.  
 
10.4.1.4  AEs of Special Interest (AESIs)  
 
AEs of Special Interest are defined as a potential safety problem, identified as a result of safety 
monitoring of the Product  
  
The Rituxan Events of Special Interest are: NONE  
10.4.2   Assessment and Recording of Adverse Events  
 
This study will utilize the CTCAE version 4.0 coding system for adverse event recording.  Adverse 
events reported using CTCAE will be recoded into MedDRA terms by the DCC.  
 
Assessment of Adverse Events  
At each visit (including telephone interviews), the subject will be asked “Have you had any 
problems or symptoms since your last visit?” in order to determine the occurrence of adverse 
events. If the subject reports an adverse event, the Investigator will determine:  
 
1. Type of event  
2. Date of onset and resolution (duration)  
3. Severity (mild, moderate, severe)  
4. Seriousness (does the event meet the above definition for an SAE)  
5. Causality, relation to investigational product and disease  
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 69 of 77 6. Action taken regarding investigational product  
7. Outcome  
 
Relatedness of Adverse Event to Investigational Product  
 
The relationship of the AE to the investigational product should be specified by the Site 
Investigator, using the following definitions:  
 
1. Not Related: Concomitant illness, accident or event with no r easonable association with 
treatment.  
2. Unlikely: The reaction has little or no temporal sequence from administration of the 
investigational product, and/or a more likely alternative etiology exists.  
3. Possibly Related: The reaction follows a reasonably tempor al sequence from administration of 
the investigational product and follows a known response pattern to the suspected 
investigational product; the reaction could have been produced by the investigational product 
or could have been produced by the subject’s clinical state or by other modes of therapy 
administered to the subject. (suspected ADR)  
4. Probably Related:  The reaction follows a reasonably temporal sequence from administration 
of investigational product; is confirmed by discontinuation of the investigat ional product or by 
re-challenge; and cannot be reasonably explained by the known characteristics of the subject’s 
clinical state. (suspected ADR)  
5. Definitely Related:  The reaction follows a reasonable temporal sequence from administration 
of investigationa l product; that follows a known or expected response pattern to the 
investigational product; and that is confirmed by improvement on stopping or reducing the 
dosage of the investigational product, and reappearance of the reaction on repeated exposure. 
(suspected ADR)  
 
Recording of Adverse Events  
 
All clinical adverse events are recorded in the AE Log in the subject ’s study binder. The site should 
fill out the AE Log and enter the AE information into the online Adverse Event Reporting System 
within 5 working  days /7 calendar days  of the site learning of a new AE or receiving an update on 
an existing AE.   
 
Please Note: SAEs must be reported to the NeuroNEXT Data Coordinating Center within 24 hours 
of the site learning of the SAE.  
 
All SAEs must be followed un til resolution, or until the Week 52 Visit, whichever comes first. If 
the SAE is still ongoing at Week 52, it will be Resolved with Sequelae.  
• SAEs that are discovered less the 90 days prior to the Week 52 Visit will be followed 
until resolution or for a m inimum of 90 days, whichever comes first , even if it is past the 
Week 52 Visit . A repeat Termination Visit does not need to occur.  
• If a new SAE is discovered at the Week 52 Visit, it must be followed until resolution, or 
for a minimum of 90 days, whichever  comes first.  
• For SAEs that result in study treatment discontinuation and a limited follow -up period, 
please refer to Section 8 – Criteria for Intervention Discontinuation.  
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 70 of 77 Entries on the AE Log (and into the online Adverse Event Reporting System) will i nclude the 
following: name and severity of the event, the date of onset, the date of resolution, relationship to 
investigational product, action taken, and primary outcome of event.  
 
Adverse Events and Serious Adverse Events - Reportable Events  
 
The following are considered reportable events and must be reported to the NeuroNEXT Data  
Coordinati ng Center within 24 hours of the site being notified of the event.  
 
• All events that meet the above criteria for Serious Adverse Events (SAEs)  
 
All occurrences of SAEs must be reported within 24 hours of discovery of the event.   All other 
AEs must be reported within  5 working days/7 calendar days of discovery of the event.  
 
Adverse Event Data Management System (AEDAMS)  
 
Upon entry of a serious ad verse event by a clinical site, the DCC Online Adverse Event Reporting 
System will immediately notify the IMM. If warranted, the IMM will notify the DSMB chair.  
 
Serious adverse events : The site investigator determines causality (definitely not related, p robably 
not related, possibly related, probably related, definitely related) of the adverse event. The IMM 
will review the SAE report.  The IMM may request further information if necessary.  The DSMB 
may suggest changes to the protocol or consent form to t he Project PI as a consequence of 
adverse events. The Online Adverse Event Reporting System maintains audit trails and stores 
data (and data updated) and communication related to any adverse event in the study.  
 
Non-serious adverse events : Non -serious adv erse events that are reported to or observed by the 
investigator or a member of his research team will be submitted to the DCC within 5 working 
days /7 calendar days . The events will be presented in tabular form and given to the IMM on a 
monthly basis or as  requested. Local site investigators are also required to fulfill all reporting 
requirements of their local institutions.  
 
The DCC will prepare aggregate reports of all adverse events (serious/not serious and expected, 
unexpected) for the DSMB.  
 
10.4.2.1  Reconciliation  
 
The Sponsor agrees to conduct reconciliation for the product. Genentech and the Sponsor will 
agree to the reconciliation periodicity and format, but agree at minimum to exchange monthly 
line listings of cases received by the other party. If  discrepancies are identified, the Sponsor and 
Genentech will cooperate in resolving the discrepancies. The responsible individuals for each 
party shall handle the matter on a case -by-case basis until satisfactory resolution.  
 
10.4.2.2  Study Close Out  
 
Any study re port submitted to the FDA by the Sponsor -Investigator should be copied to 
Genentech. This includes all IND annual reports and the Clinical Study Report (final study 
report). Additionally, any literature articles that are a result of the study should be sen t to 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 71 of 77 Genentech. Copies of such reports should be mailed to the assigned Clinical Operations contact 
for the study:  
 
 
11 HUMAN SUBJECTS  
Documented approval from the NeuroNEXT CIRB will be obt ained for all participating centers 
prior to clinical trial start, according to ICH GCP, local laws, regulations and organization. When 
necessary, an extension, amendment or renewal of the CIRB approval must be obtained.  
Evidence of training in responsible  conduct of research shall be on file for each CSS PI and co -
investigator.  
11.1 Central Institutional Review Board ( CIRB) Review and Informed Consent  
 
This protocol and the informed consent document (Appendix A) and any subsequent 
modifications will be reviewed  and approved by the NeuroNEXT CIRB responsible for oversight 
of the study.  A signed consent form, approved by the NeuroNEXT CIRB, will be obtained from 
the subject.   For subjects who cannot provide consent for themselves, such as those below the 
legal a ge, a parent, legal guardian, or person with power of attorney, must sign the consent form; 
additionally, the subject's assent must also be obtained if he or she is able to understand the 
nature, significance, and risks associated with the study.  The cons ent form will describe the 
purpose of the study, the procedures to be followed, and the risks and benefits of participation.  A 
copy of the consent form will be given to the subject, parent, or legal guardian, and this fact will 
be documented in the subjec t’s record.  
 
11.2 Subject Confidentiality  
 
All laboratory specimens, evaluation forms, reports, video recordings, and other records that leave 
the clinical study site will be identified only by the study specific Subject Identification Number 
(SID) to maintain subject confidentiality.  All records will be kept in a locked file cabinet.  All 
computer entry and networking programs will be done using study specific SIDs only.  Clinical 
information will not be released without written permission of the subject, exce pt as necessary for 
monitoring by CIRB, the FDA, the NINDS, the OHRP, the sponsor, or the sponsor’s designee.  
 
11.3 Study Modification/Discontinuation  
 
The study may be modified or discontinued at any time by the CIRB, the NINDS, the sponsor, the 
OHRP, the FDA,  or other government agencies as part of their duties to ensure that research 
subjects are protected.  
 
12 PUBLICATION OF RESEARCH FINDINGS  
 
Publication of the results of this trial will be governed by the policies of the NeuroNEXT Network 
and procedures devel oped by the NeuroNEXT Data Sharing and Publication Committee.  Any 
presentation, abstract, or manuscript will be made available for review by the sponsor and the 
NINDS prior to submission.   A copy of proposed publications or presentations should be submitt ed 
to Genentech a minimum of 2 months in advance.  
 

Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 72 of 77  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 REFERENCE S 
 
1. Conti -Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J 
Clin Invest 2006;116:2843 -54. 
2. Gold R, Schneider -Gold C. Current and future standards in treatment of myasthenia gravis. 
Neurotherapeutics 2008;5:535 -41. 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 73 of 77 3. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract 
Neurol 2008;4:317 -27. 
4. Díaz -Manera J, Martínez -Hernández E, Querol L, et al. Long -lasting treatment effect of 
rituximab in MuSK myasthenia. Neurology 2012;78:189 -93. 
5. Illa I, Diaz -Manera J, Rojas -Garcia R, et al. Sustained response to Rituximab in anti -AChR 
and anti -MuSK positive Myasthenia Gravis pat ients. J Neuroimmunol 2008;201 -202:90 -4. 
6. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized 
myasthenia gravis with rituximab. Eur J Neurol 2009;16:246 -50. 
7. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response o f patients with refractory 
myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011;4:259 -66. 
8. Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of 
refractory myasthenia gravis. Muscle Nerve 2010;41:37 5-8. 
9. Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double -blind, placebo -
controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82:970 -
7. 
10. Benatar M, Sanders DB, Burns TM, et al. Recommendations for myasthen ia gravis clinical 
trials. Muscle Nerve 2012;45:909 -17. 
11. Barohn RJ. Standards of measurements in myasthenia gravis. Ann N Y Acad Sci 
2003;998:432 -9. 
12. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing 
of the quantit ative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769 -72. 
13. Burns TM, Conaway MR, Cutter GR, Sanders DB, Group MS. Construction of an efficient 
evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008;38:1553 -62. 
14. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis 
activities of daily living profile. Neurology 1999;52:1487 -9. 
15. Burns TM, Conaway MR, Cutter GR, Sanders DB, Group MS. Less is more, or almost as 
much: a 15 -item quality -of-life instrument for myasthenia gravis. Muscle Nerve 2008;38:957 -63. 
16. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797 -810. 
17. Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. 
Neurology 2008;70:2252 -60. 
18. Dörner T, Isenberg D, Jayne D, et al. Current status on B -cell depletion therapy in 
autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 2009;9:82 -9. 
19. Dörner T, Lipsky PE. B -cell targeting: a novel approach to immune intervention today and  
tomorrow. Expert Opin Biol Ther 2007;7:1287 -99. 
20. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B -cell-targeted therapy with 
rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572 -81. 
21. Silverman GJ, Weisman S. Ritux imab therapy and autoimmune disorders: prospects for 
anti-B cell therapy. Arthritis Rheum 2003;48:1484 -92. 
22. Perosa F, Prete M, Racanelli V, Dammacco F. CD20 -depleting therapy in autoimmune 
diseases: from basic research to the clinic. J Intern Med 2010;2 67:260 -77. 
23. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin 
Hematol 2010;47:170 -9. 
24. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti -CD20 
monoclonal antibody rituximab. Ann Oncol 2003;14:520 -35. 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 74 of 77 25. Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient 
with non -Hodgkin lymphoma. Am J Hematol 2004;77:196 -7. 
26. Burusnukul P, Brennan TD, Cupler EJ. Prolonged improvement after rituximab: two cases 
of resistant muscle -specific receptor tyrosine kinase + myasthenia gravis. J Clin Neuromuscul Dis 
2010;12:85 -7. 
27. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis 
and Lambert -Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82:671 -3. 
28. Lindberg C, Bokarewa M. Rituximab for severe myasthenia gravis --experience from five 
patients. Acta Neurol Scand 2010;122:225 -8. 
29. Nelson RP, Pascuzzi RM, Kessler K, et al. Rituximab for the treatment of thymoma -
associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis 
2009;10:170 -7. 
30. Stieglbauer K, Topakian R, Schäffer V, Aichner FT. Rituximab for myasthe nia gravis: 
three case reports and review of the literature. J Neurol Sci 2009;280:120 -2. 
31. Baek WS, Bashey A, Sheean GL. Complete remission induced by rituximab in refractory, 
seronegative, muscle -specific, kinase -positive myasthenia gravis. J Neurol Ne urosurg Psychiatry 
2007;78:771.  
32. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia 
gravis. J Neurol 2007;254:968 -9. 
33. Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody -positive 
myasthenia grav is with rituximab. Muscle Nerve 2006;33:575 -80. 
34. Ibrahim H, Dimachkie MM, Shaibani A. A review: the use of rituximab in neuromuscular 
diseases. J Clin Neuromuscul Dis 2010;12:91 -102. 
35. Kundi S, Dimachkie M, Pasnoor M, McVey A, Herbelin L, R. B. Rituxi mab in generalized 
myasthenia gravis. Neurology 2010;74:A92.  
36. Palace J, Newsom -Davis J, Lecky B. A randomized double -blind trial of prednisolone 
alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 
1998;50:1778 -83. 
37. Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single -blinded trial of 
methotrexate versus azathioprine as steroid -sparing agents in generalized myasthenia gravis. BMC 
Neurol 2011;11:97.  
38. Sanders DB, Hart IK, Mantegazza R, et al. An internat ional, phase III, randomized trial of 
mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400 -6. 
39. Takagi K, Yoshida A, Iwasaki H, Inoue H, Ueda T. Anti -CD20 antibody (Rituximab) 
therapy in a myasthenia gravis patient with follicular lymphoma. Ann Hematol 2005;84:548 -50. 
40. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy 
after rituximab therapy in HIV -negative patients: a report of 57 cases from the Research on 
Adverse Drug Events and Reports project. Blood 200 9;113:4834 -40. 
41. Viegas S, Jacobson L, Waters P, et al. Passive and active immunization models of MuSK -
Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp 
Neurol 2012;234:506 -12. 
42. Lindstrom JM, Engel AG, Seybold  ME, Lennon VA, Lambert EH. Pathological 
mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental 
autoimmune myasthenia gravis in rats with anti -acetylcholine recepotr antibodies. J Exp Med 
1976;144:739 -53. 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 75 of 77 43. Oda K, K orenaga S, Ito Y. Myasthenia gravis: passive transfer to mice of antibody to 
human and mouse acetylcholine receptor. Neurology 1981;31:282 -7. 
44. Sterz R, Hohlfeld R, Rajki K, et al. Effector mechanisms in myasthenia gravis: end -plate 
function after passiv e transfer of IgG, Fab, and F(ab')2 hybrid molecules. Muscle Nerve 
1986;9:306 -12. 
45. Okumura M, Ohta M, Takeuchi Y, et al. The immunologic role of thymectomy in the 
treatment of myasthenia gravis: implication of thymus -associated B -lymphocyte subset in 
reduction of the anti -acetylcholine receptor antibody titer. J Thorac Cardiovasc Surg 
2003;126:1922 -8. 
46. Takanami I, Abiko T, Koizumi S. Therapeutic outcomes in thymectomied patients with 
myasthenia gravis. Ann Thorac Cardiovasc Surg 2009;15:373 -7. 
47. Olanow CW, Wechsler AS, Roses AD. A prospective study of thymectomy and serum 
acetylcholine receptor antibodies in myasthenia gravis. Ann Surg 1982;196:113 -21. 
48. Vincent A, Newsom -Davis J, Newton P, Beck N. Acetylcholine receptor antibody and 
clinical respo nse to thymectomy in myasthenia gravis. Neurology 1983;33:1276 -82. 
49. Mouquet H, Musette P, Gougeon ML, et al. B -cell depletion immunotherapy in pemphigus: 
effects on cellular and humoral immune responses. J Invest Dermatol 2008;128:2859 -69. 
50. Looney RJ , Anolik J, Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from 
therapy targeting B cells. Lupus 2004;13:381 -90. 
51. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell 
abnormalities in human systemic lupus erythem atosus. Arthritis Rheum 2004;50:3580 -90. 
52. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood 
and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis 
Rheum 2007;56:3044 -56. 
53. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B 
cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 
2008;58:2993 -9. 
54. Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M, Eming R. Rituximab mediates a 
strong elevation of B -cell-activating factor associated with increased pathogen -specific IgG but 
not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009;129:2202 -10. 
55. DiLillo DJ, Yanaba K, Tedder TF. B cells are required  for optimal CD4+ and CD8+ T cell 
tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 
2010;184:4006 -16. 
56. Bouaziz JD, Yanaba K, Venturi GM, et al. Therapeutic B cell depletion impairs adaptive 
and autoreactive CD4 + T cell activation in mice. Proc Natl Acad Sci U S A 2007;104:20878 -83. 
57. Eming R, Nagel A, Wolff -Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a 
dual effect in pemphigus vulgaris. J Invest Dermatol 2008;128:2850 -8. 
58. van de Veerdonk FL, La uwerys B, Marijnissen RJ, et al. The anti -CD20 antibody rituximab 
reduces the Th17 cell response. Arthritis Rheum 2011;63:1507 -16. 
59. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B -cell cytokine responses a trigger of T -cell-
mediated disease in MS? Ann Neuro l 2010;67:452 -61. 
60. Tilley BC, Palesch YY, Kieburtz K, et al. Optimizing the ongoing search for new 
treatments for Parkinson disease: using futility designs. Neurology 2006;66:628 -33. 
61. Levin B. The utility of futility. Stroke 2005;36:2331 -2. 
 
 
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 76 of 77   
Rituximab in Myasthenia Gravis  
Version 11.0 
Version date 07/05/2017  
Page 77 of 77 Appendix 1  
 
 
 
 
SAFETY REPORTING FAX COVER SHEET  
GENENTECH SUPPORTED RESEARCH  
AE / SAE FAX No: (650) 225 -4682  
Alternate Fax No: (650) 225 -5288  
 
Genentech Study Number   
Principal Investigator   
Site Name   
Reporter name   
Reporter Telephone #   
Reporter Fax #  
 
 
Initial Report Date  [DD] / [MON]  / [YY] 
Follow -up Report Date  [DD] / [MON]  / [YY] 
Subject Initials  
(Enter a dash if patient has no 
middle name)  [ ] - [ ] - [ ] 
 
SAE or Safety Reporting questions, contact Genentech  Safety: (888) 835 -2555  
 
PLEASE PLACE MEDWATCH REPORT or SAFETY REPORT BEHIND THIS COVER SHEET  
 
